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Women are disproportionately affected by HIV, with most infections in women occurring as a 
result of heterosexual intercourse. New HIV prevention strategies are needed that women could 
employ discretely, potentially without consulting male partners. Vaginal spermicidal gels and 
films can successfully prevent pregnancy, and similar products can be used to deliver 
antiretroviral medications. This thesis presents two phase 1 studies of vaginal microbicides 
containing dapivirine or tenofovir and will demonstrate that these products are safe, effective, 
and successfully deliver their respective antiretrovirals in the vaginal environment. 
 
The FAME 02b study describes pharmacokinetic and pharmacodynamic evaluation of a single 
dose of dapivirine vaginal gel and film. By assessing drug concentrations in plasma, 
cervicovaginal fluid, and cervical tissue, we show that both vaginal film and gel formulations are 
able to deliver concentrations of dapivirine to these anatomic locations that should be protective 
against HIV infection. An explant HIV infectivity assay performed on cervical tissue biopsy 
specimens supports the further development of both dapivirine products. 
 
The FAME 05 study employs a complementary design to FAME 02b to evaluate similar film and 
gel products containing tenofovir. The same schedule and type of samples were collected 
following a single dose of tenofovir vaginal film or gel, including the cervical tissue explant 
assay, with the addition of rectal fluid drug concentration. Tenofovir film was associated with 
higher drug concentrations in plasma, cervicovaginal fluid, and cervical tissue, while rectal fluid 
tenofovir was higher after gel dosing. There was no difference between the two products in 




Early studies of both oral and vaginal pre-exposure prophylaxis against HIV were promising, 
finding up to 70% protection from HIV acquisition when products were used consistently. 
Follow-up randomized clinical trials failed to confirm the protective effect of either form of PrEP 
among women, partly due to poor product adherence. New vaginal microbicides that can be used 
episodically around the time of intercourse may be more preferable to some women than a daily 
preventive medication. Clinical trials of dapivirine and tenofovir vaginal gels and films are 
warranted in order to provide a variety of HIV prevention strategies. 
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Women currently make up more than half of the over 36 million adults and children worldwide 
who are infected with the human immunodeficiency virus (HIV)1. Sub-Saharan Africa is the 
region of the world most affected by the HIV epidemic, with over a dozen countries reporting 
HIV prevalence rates greater than 5% among women2.  Only about half of people living with 
HIV have access to antiretroviral treatment1. Preventing new HIV infections remains an 
important international health goal3, and while significant strides in reducing the spread of HIV 
have been made, there remains a need for new interventions. 
 
Heterosexual intercourse (and specifically penile-vaginal intercourse) remains the most common 
route of infection for women living with HIV.  Young women have been found to have higher 
incident HIV infection compared to men in the same age group4. There are many structural and 
behavioral factors that enhance women’s susceptibility to HIV including poverty, concurrent 
sexual relationships, transactional sex, and difficulty negotiating condom use5. There may also 
be biological differences that increase women’s likelihood of HIV acquisition through penile-
vaginal intercourse.  Hormonal changes that occur during the phases of the menstrual cycle, or 
during pregnancy and the postpartum period, appear to influence HIV susceptibility. The 
presence of other sexually transmitted infections, such as herpes simplex virus or human 
papilloma virus, have also been linked with increased risk of acquiring HIV.  
 
The projects presented in this thesis are early drug development studies of two nucleoside 
reverse transcriptase inhibitors administered as vaginal microbicides.  The FAME 02b and 
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FAME 05 studies describe the pharmacokinetics and pharmacodynamics of a single dose of 
dapivirine vaginal gel or film (FAME 02b) or tenofovir vaginal gel or film (FAME 05). These 
studies informed subsequent trials of serial doses of tenofovir and dapivirine vaginal gel and 
film6,7, demonstrating that these products were safe, well-tolerated, and have the potential to 
reduce a woman’s risk of HIV acquisition through heterosexual intercourse. 
 
Having female-controlled prevention strategies has the potential to overcome some of the 
weaknesses of relying on male condoms, which while they are effective at preventing 
transmission of HIV when used, are not always used consistently or correctly.  Oral microbicides 
to prevent HIV transmission have been shown to be effective, but they suffer from several 
shortcomings including that people do not take them reliably.  It may be preferable for some 
women and couples to have prevention products that are intended to be used only at the time of 
intercourse, so that they do not have to remember a daily dosing schedule.  It is also 
advantageous for women to be able to use a product without needing the consent of her male 
partner. These gaps in prevention strategies have the potential to be filled by vaginal 
microbicides. 
 
1.2 Pre-Exposure Prophylaxis for HIV Prevention 
Since the beginning of the HIV epidemic, the primary strategy for prevention of sexual 
transmission has been to encourage the correct and consistent use of male condoms.  Despite 
extensive efforts to facilitate and encourage condom use, even by known serodiscordant partners, 
this strategy has been ineffective in slowing the spread of HIV.  Only since highly-active 
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antiretroviral therapy (HAART) for treatment of HIV has been made widely available has there 
been any measurable decrease in global HIV transmission3. 
 
The next big leap forward in HIV prevention was made when it was determined that daily oral 
dosing of tenofovir (TFV, TDF) and emtricitabine (FTC) as pre-exposure prophylaxis (PrEP) 
could reduce an individual’s risk of HIV acquisition. The iPrEx study was the first randomized, 
placebo-controlled trial evaluating whether daily oral TDF-FTC could reduce HIV transmission 
among trans-women and men who have sex with men8. The overall reduction in HIV risk was 
44% in the TDF-FTC group, but the protective effect of oral PrEP was as high as 92% among 
participants who had detectable study drug levels in their blood 8. The Partners PrEP study used 
a similar design among serodiscordant heterosexual couples, although this trial included a third 
arm in which the HIV-negative partner received daily oral TDF without FTC9. The Partners 
PrEP Study found even more promising results than iPrEx: an overall 75% risk reduction in HIV 
acquisition with TDF-FTC, with protection as high as 90% among participants with detectable 
study drug levels (compared to those without detectable drug levels)9. There was no difference in 
the protective effects of TDF-FTC in women compared to men. 
 
Subsequent studies specifically investigating the efficacy of oral PrEP in women found 
disappointing results. In FEM-PrEP, HIV-negative women were randomized to take either daily 
oral TDF-FTC or placebo, in a design mirroring the iPrEx trial. Unlike in iPrEx or Partners 
PrEP, FEM-PrEP found no difference in HIV acquisition with oral PrEP compared to placebo 
(HR 0.94, 95% CI 0.59-1.52, p=0.81)10. Participants in FEM-PrEP reported a high level of 
adherence to the daily PrEP regimen, and pill counts were consistent with 88% adherence. 
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However, when plasma tenofovir concentrations were measured in HIV seroconverters and 
matched controls, adherence ranged from 15% to 37%10. The VOICE trial had similar adherence 
challenges. In VOICE, HIV-negative women were randomized to daily use of one of five 
products: oral TDF, oral TDF-FTC, oral placebo, TFV vaginal gel, or placebo vaginal gel11.  
Compared to placebo, there was no difference in HIV acquisition with oral TDF (HR 1.49, 95% 
CI 0.97-2.29, p=0.07), oral TDF-FTC (HR 1.04 (0.73-1.49, p=0.81), nor TFV vaginal gel (HR 
0.85, 95% CI 0.61-1.21, p=0.37). Despite high levels of adherence by participant self-report 
(mean = 90%) and returned product counts (mean = 86%), half of the participants assigned to the 
active product arms had no detectable tenofovir in plasma at any quarterly visit. When 
participants who had detectable concentrations of TFV in plasma were compared to those 
without, TFV in plasma was associated with greater than 60% reduced likelihood of HIV 
infection (adjusted HR 0.34, 95% CI 0.13-0.87, p=0.02). 
 
Data regarding vaginal microbicides for HIV prevention have been similarly mixed. CAPRISA 
004 was the first randomized trial to demonstrate efficacy of a vaginal product at reducing HIV 
acquisition. In this study, a 1% TFV vaginal gel applied before and after intercourse (pericoital 
use) led to an overall 39% decrease in risk of HIV infection compared to placebo, with the risk 
reduction as high as 54% among women with high adherence 12. In contrast, VOICE found no 
difference in HIV risk among women randomized to daily use of 1% TFV vaginal gel compared 
to placebo 11.  The FACTS 001 trial repeated the design of CAPRISA 004 (pericoital use of 1% 
TFV vaginal gel vs placebo) on a larger scale, but found no difference in HIV acquisition 
between arms (IRR 0.98, 95% CI 0.7-1.4)13. In a subgroup analysis, women with high 
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concentration of TFV in cervicovaginal lavage samples had a 48% lower risk of HIV acquisition 
(aHR 0.52, 95% CI 0.27-0.99). 
 
1.3 Microbicides in HIV Prevention 
Microbicides are products designed to be applied to the vagina or rectum prior to intercourse 
with the goal of reducing the risk of HIV acquisition by the receptive partner.  An ideal 
microbicide should maintain the integrity of the mucosal epithelium, distribute into the tissues 
where HIV infection likely occurs without significant systemic absorption, and persist in the site 
of application for sufficient time to provide protection14. Products must also be acceptable to the 
individuals for whom they are designed. Early products studied as vaginal microbicides included 
various vaginal gels (nonoxynol-9, cellulose sulfate, surfactant, BufferGel®, Carraguard®) 
without antiretroviral drugs. These products were thought to prevent HIV transmission by 
various mechanisms including altering blocking HIV adherence and entry into target cells, 
altering the vaginal mucosa, or maintaining the acidic pH of vaginal fluid14. Despite promising 
results from animal studies, human trials failed to demonstrate efficacy at preventing HIV 
transmission. 
 
Several drugs have been investigated as microbicide candidates, with promising results seen for 
tenofovir and dapivirine. Tenofovir is a nucleoside reverse transcriptase inhibitor (NRTI)15 that 
is a key component of first-line oral HAART regimens used for treatment of HIV16. Tenofovir 
has been shown to be effective for HIV prevention when taken orally by individuals at high risk 
of HIV infection and is well tolerated with few serious side effects9.  The oral formulation of 
tenofovir is a prodrug of the active compound tenofovir diphosphate (TFV-DP) which inhibits 
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HIV replication in target cells17. An oral formulation of tenofovir combined with emtricitabine 
(another nucleoside reverse transcriptase inhibitor) is the only product currently being marketed 
as HIV pre-exposure prophylaxis18. Dapivirine is a non-nucleoside reverse transcriptase inhibitor 
(NNRTI) that has poor oral bioavailability, but when dosed via a non-oral route has potent anti-
HIV activity19. Dapivirine is being investigated for HIV prevention in the forms of vaginal 
film6,20, gel21,22, and ring delivery systems23-27. 
 
A successful microbicide drug must have several features including the ability to penetrate the 
mucosa of the application site (vagina or rectum) and achieve sufficient concentrations in the 
local environment to prevent HIV transmission.  Microbicides are generally not trying to achieve 
systemic drug concentrations; the local presence of drug in the vagina or rectum is most 
important in reducing HIV transmission. The systemic drug concentrations are important for 
determining the likelihood of adverse drug effects and could also contribute to antiretroviral 
resistance if a user seroconverts despite using the microbicide. 
 
1.4 FAME 02b and FAME 05 
The FAME 02b and FAME 05 studies were designed to assess the pharmacokinetic properties of 
tenofovir and dapivirine gels and films in various compartments. Participants received a single 
dose of dapivirine (FAME 02b) or tenofovir (FAME 05) vaginal gel or film and subsequently 
underwent serial sampling of serum, rectal fluid (FAME 05 only), cervicovaginal fluid (CVF), 
and cervical biopsies over the next 7 days. Half of study participants were randomized to be 
dosed with gel first, followed by film after a washout period. The other half were randomized to 
be dosed with film, followed by gel.  Serum, rectal fluid, CVF, and cervical biopsies were 
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assessed for relevant drug concentrations.  Cervical biopsies collected after study product dosing 
and collected off all study products were used in explant challenges to assess for HIV infectivity 
in the presence and absence of drug. 
 
All products assessed in these studies were found to be well tolerated, with no serious adverse 
events and no AEs deemed related to study product use.  Dapivirine concentrations in all 
compartments assessed were similar after film and gel dosing.  In contrast, tenofovir film was 
associated with higher CVF and cervical tissue drug concentrations than tenofovir gel, while the 
tenofovir gel was associated with higher rectal fluid concentrations than film. Cervical tissue 
explant challenge suggested protective effect of dapivirine vaginal products but not tenofovir, 
although there was significant variability in results for all four products. Taken together, these 
studies indicate that vaginal films and gels containing dapivirine and tenofovir are promising 






FAME 02b Study 
 
This chapter is published as “Robinson JA, Marzinke MA, Bakshi RP, Fuchs EJ, Radebaugh CL, 
Aung W, Spiegel HM, Coleman JS, Rohan LC, Hendrix CW. Comparison of dapivirine vaginal 
gel and film formulation pharmacokinetics and pharmacodynamics (FAME 02B). AIDS Res 
Hum Retroviruses. 2017 Apr;33(4):339-346. Pubmed PMID: 27809557.” 
 







While pre-exposure prophylaxis with oral tenofovir/emtricitabine has proven effective in 
reducing HIV acquisition rates, poor adherence to and acceptability of existing vaginal gels and 
the potential for evolving drug resistance to proven agents has led to development of vaginal film 
formulations and other antiretroviral drugs, respectively, including the non-nucleoside reverse 
transcriptase inhibitor dapivirine.  
2.1.2 Study Design 
In this two-arm, cross-over study of a novel fast-dissolving dapivirine film and a previously 
studied semisolid dapivirine gel, nine healthy women received a single 1.25 mg vaginal dose of 
each study product (a total of 10 women enrolled, but one withdrew after the first dosing visit). 
Clinical, pharmacokinetic, and antiviral pharmacodynamic assessments (ex vivo HIV-BaL 
challenge of tissue explants) were performed over 7 days following dosing.  
2.1.3 Results 
Six of the 10 research participants experienced mild to moderate adverse effects, similar between 
products, with no severe adverse events or adverse events attributed to study products. There 
were no statistically significant differences in plasma, cervicovaginal fluid (CVF), or cervical 
tissue dapivirine concentrations between the gel and film (all p>0.05). CVF dapivirine 
concentrations were 1.5 log10 and 6 log10 greater than tissue and plasma concentrations, 
respectively (p<0.001). Both film and gel demonstrated antiviral effect in explant challenges of 
cervical biopsies collected 5 hours after dosing, compared to biopsies collected without drug and 
72 hours after dosing (p<0.05 for gel, p=0.06 for film). There was no difference in ex vivo 




The dapivirine film and gel performed similarly in terms of tolerability, pharmacokinetics, and 
antiviral effect. The film product may provide an acceptable alternative to pharmacokinetically 
comparable dapivirine gel formulations. Effectiveness remains to be tested. 
 
2.2 Introduction 
Infection with human immunodeficiency virus (HIV) remains a global health problem, with 2 
million new HIV infections reported worldwide in 2014 28. Sexual transmission remains the most 
common mode of transmission, particularly for young women.  A promising strategy to reduce 
sexual transmission of HIV is the use of pre-exposure prophylaxis (PrEP), during which a person 
takes or applies a drug or combination of drugs in order to reduce his or her risk of HIV 
acquisition. Randomized placebo controlled trials of PrEP using daily oral 
tenofovir/emtricitabine 29 and peri-coital 1% tenofovir vaginal gel 12 demonstrated that high 
levels of product adherence result in reduced HIV acquisition 8,9,30-32. Poor adherence resulted in 
no protective effect of the same drug regimens 11,33,34. 
 
Alternative behavioral and biomedical strategies intended to improve adherence to PrEP 
regimens include: sustained release products that require infrequent dosing and provide long-
term protection, or topical products that may be suitable for periodic dosing and provide 
alternatives to oral dosing desired by some 35-37. Sustained delivery product development 
includes: antiretroviral (ARV) vaginal rings replaced monthly; intramuscular injectable 
formulations of ARVs dosed every 2 months; and implantable ARV formulations with potential 
for yearly dosing as indicated by pre-clinical pharmacokinetic (PK) studies 38. Alternative topical 
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approaches in development include vaginal films and tablets, rectal gels, suppositories, and 
enemas; these efforts include tenofovir and several other candidate ARV compounds, including 
dapivirine. 
 
Dapivirine (DPV) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that has potent 
anti-HIV-1 activity, both in vitro and in vivo 39. While it has very poor oral absorption, making it 
impractical for oral dosing, DPV has shown promise as a topical microbicide.  Studies 
investigating rings, films, and gels that deliver various doses of DPV have shown the products to 
be safe and well tolerated when dosed vaginally in women 22,25,40-45. A DPV gel developed for 
vaginal use proved safe and acceptable to men, when applied externally to the penis 46. 
 
Sustained delivery products are not necessary for persons with only periodic risk of HIV 
infection, and some individuals may choose to avoid the increased and sustained risk of systemic 
toxicity associated with injectable formulations. On-demand microbicide (topical formulation) 
products for use during periods of anticipated sexual exposure to HIV may be a suitable 
alternative for such persons. Most of the microbicide products evaluated for effectiveness have 
been aqueous-based gels applied peri-coitally 11,30,34. While efficacy was low or absent in several 
randomized clinical trials of vaginal tenofovir gels in intent to treat analyses (CAPRISA 004, 
VOICE, FACTS 001), efficacy was demonstrated in the subset of individuals with high levels of 
adherence in all of these studies 47.  
 
One limitation of the vaginal gel identified in acceptability studies included the participant 
experience with the product, as the gel often leaked from the vagina after application, as well as 
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the bulkiness of the applicator that complicated product storage and transport 48. A quick 
dissolving vaginal film dosage form – far smaller in size, less packaging to dispose of post-
application, less volume to leak from the vagina, and less volume to dilute innate endogenous 
antibacterial and antiviral properties of vaginal fluid – may overcome some limitations of gel 
products which impact adherence. The Listerine® breath mint strips are a familiar and 
acceptable fast-dissolving film formulation for oral dosing. Vaginal films, like the nonoxynol 9 
contraceptive film, have proven more acceptable than gel formulations 49,50.  
 
For this study (FAME 02B), we used a soft, flexible, translucent DPV vaginal film composed of 
a polyvinyl alcohol (PVA) base, with an individual unit size of 1” × 2”, and 70 μm thick. In vitro 
studies show the films dissolve rapidly upon exposure to an aqueous environment, releasing 
more than half of the DPV within 10 minutes 20. Each individual film contains 1.25 mg of DPV 
and is comparable to phase 1 studies of DPV gels (0.05% with administration of 2.5 g/2.8 mL). 
Studies of DPV vaginal gel (including companion study, FAME 02) have shown that these 
products are safe, generally acceptable to women (apart from leakiness noted above), and lead to 
low systemic DPV concentrations22,42,43,45. 
 
The current study describes the multi-compartment pharmacokinetics (blood, cervical tissue, and 
cervicovaginal fluid [CVF]) and ex vivo pharmacodynamics (HIV tissue explant challenge) over 
one week following a single dose of DPV film compared to a DPV gel formulation. The 
companion study, FAME 02, involved one week of daily dosing of the same DPV film and gel 




2.3 Materials and Methods 
2.3.1 Study Design and Participants 
This was a two-arm, single site, randomized cross-over study of two DPV formulations, 
conducted at the Drug Development Unit (DDU) of the Johns Hopkins Hospital in Baltimore, 
MD.  The protocol was approved by the Johns Hopkins Medicine Institutional Review Board.  
Ten healthy, HIV-uninfected women between the ages of 18 and 45 years were recruited to 
participate.  After ensuring eligibility, participants were randomized to receive either DPV 
vaginal gel (0.05%, 2.5 g/2.5 mL volume, total 1.25 mg applicator dose) followed by DPV 
vaginal film (1.25 mg/film), or film followed by gel.  At the first study visit, the DPV gel product 
was applied by an investigator using a polyethylene vaginal applicator (HTI Plastics, Lincoln, 
NE). The DPV film product was applied in the mid-vaginal region by a gynecologist during a 
speculum exam. The participant remained recumbent for approximately 30 minutes after each 
dose.  Over the next 12 hours, serial blood samples for DPV concentration were collected, and 
samples of rectal fluid (RF), CVF, and cervical biopsies were collected 5 hours after dosing. 
CVF samples were taken from 3 locations within the lower female genital tract – mid-vagina, 
posterior vaginal fornix, and external cervical os using a Dacron swab (Cardinal Health, 
McGraw Park, IL).  Participants returned to the DDU to provide blood samples at 24, 48, 72, and 
168 hours after dosing.  Cervical biopsies were repeated at the 72-hour visit, and CVF samples 
were collected at 72 and 168 hours.  A final safety assessment for the first study product was 
conducted 14 days after dosing, after which the second formulation was dosed at a similar time 
during the participant’s next menstrual cycle.  The second study product was followed by the 
same sampling schedule. A final set of cervical biopsies was collected from each participant 
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several weeks after completing the second product dosing, in order to serve as a negative control 
for ex vivo explant assessments. 
 
2.3.2 Clinical Assessment 
Participants were assessed for adverse events (AEs) at each study visit, and if detected, each AE 
was assigned a grade based on the Division of AIDS (DAIDS) Table for Grading Adult and 
Pediatric Adverse Events, Version 1.0 and the Female Genital Grading Table for Use in 
Microbicide Studies (Appendix 1 to DAIDS Table for Grading Adult and Pediatric Adverse 
Events, Version 1.0) 51,52.   
 
2.3.3 Pharmacokinetic Sample Analysis 
Plasma DPV concentrations were measured using a validated ultra-performance liquid 
chromatographic-tandem mass spectrometric (LC-MS/MS) method that has been previously 
described 53.   The lower limit of quantification (LLOQ) for this assay is 20 pg/mL, with 
coefficient of variation (%CV) for intra- and inter-assay precision and accuracy ranging from 
5.23 to 13.89.   
 
Cervicovaginal fluid samples were analyzed for DPV concentration using validated LC-MS/MS 
analysis, with LLOQ of 0.250 ng/swab, corresponding to median 0.01 ng/mg based on CVF 
sample volumes. Cervical tissue DPV concentration was assessed, following homogenization 
and protein precipitation, using a validated LC-MS/MS method with a LLOQ of 0.05 ng/sample, 
corresponding to median 0.07 ng/mg based on biopsy weights 44. Tissue DPV quantification was 
performed using calibrators prepared in human plasma and matrix-specific tissue quality control 
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samples. The assay for rectal fluid (RF) DPV quantification is still being validated; 
consequently, these results are not presented. 
 
2.3.4 HIV Exposure and HIV-1 p24 Measurement 
Two cervical biopsies from each study product and time point (5 hour, 72 hour) and the no drug 
control were collected in L15 media (Mediatech, Manassas, VA), 1x Pen/Strep/Glutamine, 1x 
Amphotericin B, and 10% FBS (Gemini BioProducts, Woodland, CA). Biopsies were 
individually transferred to single wells of a 48 well plate containing 1 mL culture medium - 
DMEM (Mediatech, Manassas, VA) with 10% human AB serum (Gemini BioProducts, 
Woodland, CA), 1x Pen/Strep/Glutamine (Gemini BioProducts, Woodland, CA), 1x Non-
essential amino acids (Mediatech, Manassas, VA) and 100 units IL-2 (Roche). Biopsies were 
exposed to HIV-1 BaL at final concentration of 5 x 104 TCID50/mL and incubated for 2 h at 37 
°C and 5% CO2 in 100% humidity. After infection, biopsies were washed 4 times with 1 mL 
HBSS, weighed, and transferred to separate wells of a 48 well plate (1 biopsy/well) containing 1 
mL fresh culture medium (described above). The day of infection was denoted as Day 0. Plates 
were incubated for 14 days at 37 °C and 5% CO2 in 100% humidity. 0.7 mL culture medium was 
harvested on days 4, 7, 10 and 14 and replaced with fresh medium. Harvested medium was 
stored frozen at -20 °C until analysis. HIV-1 p24 concentration in the harvested medium was 
measured using the PerkinElmer Alliance HIV-1 p24 ELISA kit according to manufacturer’s 
instructions. Cumulative p24 produced by biopsies over 14 days was used for analysis. 
 
2.3.5 Statistical Analysis 
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Plasma values were analyzed calculating area under the concentration-time curve from 0 to last 
sample (AUClast), peak concentration (Cmax), and time to peak concentration (Tmax) with 
noncompartmental methods using Phoenix WinNonlin® software (version 6.4, 
Pharsight/Certara, Princeton, NJ). Crude maximum half-life estimates for CVF and cervical 
tissue DPV were also calculated using imputation of LLOQ/2 where concentration fell below the 
LLOQ. (Note: these are poor estimates due to very sparse sampling [2 tissue and 3 CVF 
samples] with highly uncertain time to both Cmax and LLOQ. Guided somewhat by plasma Tmax 
data, the calculated estimates are highly conservative and are very likely longer than the true 
elimination half-life.) Concentration-time data is presented using SigmaPlot®, Version 13 
(Systat Software, Inc., San Jose, CA).  Descriptive statistics of data and comparisons between the 
two formulations and between different matrices were performed using the Wilcoxon rank sum 
test using Stata®, Version 12 (StataCorp LP, College Station, TX). Differences in CVF among 
the 3 lower female genital tract sites were tested first with the Friedman test, followed by post 
hoc paired comparisons (Wilcoxon test). A p-value of less than 0.05 was considered statistically 
significant in comparison testing and correlation. 
 
The DPV concentration-response (cumulative p24) relationship was explored through (1) testing 
correlation of DPV tissue concentration and cumulative p24 (Spearman correlation coefficient), 
(2) linear least-squares regression modeling (using raw and log-log transform of p24 and DPV 
concentration) with participant and formulation (film v. gel) as covariates, and (3) a series of 
pharmacodynamic models using the Hill equation to estimate concentration at which antiviral 
effect is 50% of maximum (IC50), maximum inhibitory effect (Imax), baseline effect (no drug), 
and sigmoidicity (Hill coefficient) using Phoenix WinNonlin v 6.4 (Pharsight/Certara, Princeton, 
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NJ). Correlation and pharmacodynamic modeling were performed by both excluding all BLQ 




Participants were mean (standard deviation [SD]) 28.7 (±8.3) years of age. Half of participants 
(n=5) were African-American, with non-Hispanic white, Hispanic, Asian, and mixed race among 
the other 5.  One participant withdrew from the study after her first product dosing (film) and did 
not have any samples collected after the first day.  Pharmacokinetic and pharmacodynamic data 
are presented from the remaining 9 participants who have complete data, while adverse event 
data are presented from all 10 enrolled participants. 
 
2.4.2 Adverse Events 
A total of 24 AEs were recorded throughout the study, all of which occurred in 6 of 10 
participants (i.e.: 4 participants experienced no AEs).  The AEs were reported within the week 
following dosing, except for one AE at baseline (known history of iron-deficiency anemia) and 
two identified at the follow up visit that occurred between the first and second dosing visits. 
Reported adverse events included: headache, diarrhea, periorbital edema, upper respiratory 
infection, phlebotomy site bruising, urinary tract infection, mononucleosis, and dehydration; lab 
abnormalities included hypoglycemia, hyperglycemia, anemia, hypokalemia and increased 
neutrophil count.  No serious AEs (SAEs) were recorded for any participant, and the majority of 
AEs were Grade 1 (only 6 of 24 were Grade 2, which occurred in two participants).  Of the AEs 
that occurred during dosing intervals (n=21), they were evenly distributed between the two 
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products (11 occurred with gel, 10 occurred with film).  All AEs were determined to be “not 
related” to study product exposure. 
 
2.4.3 Pharmacokinetics 
Following dosing of each product, plasma DPV concentrations rose to a peak between 12 and 24 
hours, then fell in log linear fashion; at the last observation, 168 hours, 5 of 9 participants (2 
film, 3 gel) had detectable plasma DPV concentrations (Figure 2.1A). Median (IQR) plasma PK 
parameter estimates for the film product were: Cmax 91 (67, 179) pg/mL, Tmax 12 (5, 18) hours, 
AUClast 7,952 (5,763, 9,021) pg-hrs/mL, and half-life 59 (51, 82) hours. Gel PK parameter 
estimates were: Cmax 132 (93, 169) pg/mL, Tmax 24 (10, 24) hours, AUClast 7,832 (5,799, 11,807) 
pg-hrs/mL, and half-life 52 (42, 64) hours. There were no statistically significant differences 
between the film and gel products for any PK parameter (Wilcoxon rank sum, all p-values 
>0.05). 
 
CVF DPV concentrations declined from 5 through 168 hours in log linear fashion (Figure 2.1B); 
at 168 hours, all DPV concentration medians (though not all upper quartiles) were BLQ for both 
products at all sites. Accordingly, because we did not have reliable concentration estimates for 
the 168 hour time point, half-life estimates were not made. There were no statistically significant 
differences between study products for DPV CVF concentrations at any sampling location (Table 
2.1, all p>0.05). Within participants, there were statistically significant differences among the 3 
genital tract CVF sampling site concentrations for both film and gel (Table 2.1; Friedman test 
both p<0.02); in pairwise comparisons between sites, the general concentration trend was mid 




Cervical tissue homogenate DPV concentrations were also not different comparing film to gel 
(Table 2.1, Figure 2.1B). At 72 hours after dosing, only 3 of 9 samples after gel and none of 9 
samples after film had DPV cervical tissue homogenate concentrations above the LLOQ. 
Comparing concentrations across biological matrices 5 hours after study product dosing (where 
all matrices for all products and subjects are in the quantifiable range), CVF DPV concentrations 
(median across the 3 genital tract) were 1.5 log10 greater than tissue concentrations and 6 log10 
greater than plasma concentrations. Plasma half-life was significantly greater than estimated 
maximum half-life for both CVF and cervical tissue, which were similar to each other. No 
statistical comparisons are made between products or among matrices since these CVF and 
cervical tissue half-life estimates are very crudely based on too sparse data (2 to 3 samples, 5 
hour concentrations very likely before peak concentration is achieved, uncertain time to LLOQ, 
31% overall BLQ values requiring imputation).  
 
2.4.4 Pharmacodynamics (HIV-1 p24 Measurement) 
At least 7 of 9 participants’ 5-hour cumulative p24 antigen concentrations were lower than 
baseline and the 72-hour values for the corresponding product (Figure 2.2A). For cervical 
biopsies collected 5 hours after film dosing, the cumulative p24 antigen production, median 1.0 
pg/mg (IQR 0.5, 252), was significantly less than the cumulative p24 antigen 72 hours after film 
dosing, 136 pg/mg (2, 3258) (Wilcoxon rank sum test p=0.01) and trended toward being less 
than the no study product baseline, 55 pg/mg (3, 297) (p=0.07). After gel dosing, 5-hour and 72-
hour cumulative p24 concentrations were 1.0 pg/mg (1.0, 1.5) and 543 pg/mg (71, 3437), 
respectively, with 5 hour values trending toward statistical significance (p=0.06) when compared 
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to 72 hour values, and were significantly lower than no study product baseline values (p=0.04). 
Baseline values were not different than 72 hour values for either product (p>0.10). Neither was 
there any statistically significant difference in p24 production at either 5 or 72 hours post dose 
when gel was compared to film.  
 
Figures 2.2A and 2.2B demonstrate a highly variable 4 log10 spread of cumulative p24 
concentrations from baseline cervical biopsy samples (no drug) as well as for cervical samples 
collected within 72 hours of dosing, nearly all of which have BLQ DPV concentrations. Using 
all baseline biopsies and biopsies with BLQ DPV concentrations as “no drug” biopsies, within 
participant variability was median 169% (IQR 103%, 242%) coefficient of variation; overall 
coefficient of variation among all “no drug” biopsies was 262%.  
 
DPV tissue concentration was inversely correlated with cumulative p24 values, demonstrating a 
rough concentration-response relationship (Spearman correlation coefficient = -0.483, p=0.003). 
With log-log transformation of values, an inverse linear relationship between DPV concentration 
and p24 production was seen (ß = -0.82 [0.26 SE], p=0.004) with participant (ß = -0.12 [0.05], 
p=0.03), but not the product arm (ß = 0.79 [0.47], p=0.11) as significant covariates. The data 
failed to fit any non-linear inhibitory pharmacodynamic models (no statistically significant 
parameter estimates; data not shown).  
 
2.5 Discussion 
Our single-dose comparison study indicated that both DPV film and gel were well tolerated by 
study participants, with no serious adverse events reported after single doses of either product 
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and there were no differences in adverse events between products.  There were also no 
statistically significant PK differences between the two formulations in plasma, tissue, or CVF, 
except for a statistical trend toward a 2-fold greater DPV mid-vaginal CVF concentration with 
film compared to gel. There were, however, differences in DPV concentrations among anatomic 
sites at similar sampling times, generally highest at the mid vaginal position, especially 
compared to the cervical os, for both formulations. Five hours after product dosing, when drug 
was readily detectable in all participants’ samples, DPV concentrations were far greater in CVF 
compared with either cervical tissue (32-fold greater) or plasma (106-fold greater). Plasma DPV 
half-life (greater than 50 hours) was at least several times longer than the cervical tissue DPV 
half-life (<10 hours, a significant overestimate).  
 
These anatomic differences are very similar to 2 other DPV studies (FAME 02 and MTN-013) 
where the samples were analyzed in the same laboratory and paired samples from the same 
women are available for plasma, cervical tissue, and CVF44,45. FAME 02 compared daily use of 
the same DPV film and gel products as this study, though for a total of consecutive 7 days.  In 
their analysis, Bunge, et al., found that 2-4 hours after the final dose, DPV concentrations in 
cervicovaginal lavage (CVL) samples were 4 log10 greater than in plasma, and were the same as 
in cervical tissue. Median DPV plasma concentrations (220-310 pg/mL) drawn 2 to 4 hours after 
the final dose were higher than our values by 2-fold, but samples were collected after 7 daily 
doses which allows for DPV accumulation in plasma due to a long DPV half-life relative to the 
daily dosing interval. Median DPV tissue concentration following daily dosing for 7 days was 
the same as what we detected after a single dose (2 to 7 ng/mg) – no accumulation between our 
single and their 7 daily doses is also consistent with a half-life in tissue that is much shorter as 
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compared to plasma. The anatomical differences we showed - vaginal greater than cervical os 
CVF DPV concentration - is consistent with FAME 02 which showed greater DPV 
concentrations and antiviral effect (ex vivo explants) in vaginal tissue compared to cervical 
tissue. Median CVL concentrations were 2 to 5 ng/mg, which is ~20 to ~60-fold lower than our 5 
hour CVF concentrations, but the dilutional effect of the 10 mL lavage volume on drug in 100-
300 µL resident CVF volume largely accounts for this difference. No accumulation would be 
expected in CVF since the products were identical and repeated dosing should have no effect in 
CVF concentrations. So, accounting for the multiple dose accumulation of DPV in plasma and 
the dilutional effect of lavage fluid on CVF, the DPV PK findings are very similar to what was 
observed in this study.  
 
Unlike our single dose study, FAME 02 noted a statistically significant greater tissue DPV 
concentration after gel dosing when compared to film dosing. The FAME 02 report suggested 
that the tissue DPV concentrations after gel dosing were increased, when compared to film, 
likely due to residual gel adherent to the tissue biopsies; sample handling, therefore, might have 
differed between studies. In addition, in our FAME 02B study, a gynecologist administered all 
film doses whereas in FAME 02, research participants self-administered film doses, some of 
whom had difficulty. The concentration differences we noted might also be attributed to 
speculum-assisted placement in mid-vagina (5 hour samples) or study-related sampling (72 
hours). Finally, FAME 02 was a much larger study and had greater statistical power to detect 
differences than FAME 02B; however, FAME 02B actually trended in the other direction (film 
greater than gel tissue DPV concentration). Taken together, these differences support the finding 




In MTN-013, a 28-day DPV ring comparison study, the average daily dose was 0.16 mg based 
on the 25 mg DPV ring content as manufactured and 82% DPV dose retained in the rings, on 
average, after 28 days intravaginally 44. This is roughly 13% of the 1.25 mg film and gel dose in 
FAME 02 and FAME 02B. The mean (SD) steady-state (or 28 day) concentrations in MTN-013 
were: plasma, 175 (45) pg/mL, which exceeds our single dose median peak plasma DPV 
concentrations and falls below the plasma concentrations reported in FAME 02, indicating both 
accumulation of plasma DPV with time as well as more efficient drug delivery per administered 
dose with the sustained DPV release from the ring; cervical tissue, 0.6 (0.9) ng/mg, which falls 
below our single dose 5 hour (and FAME 02’s steady-state 2-to-4 hour sampled) post-dose 
cervical tissue concentrations, though proportionally higher than expected accounting for the 
lower average daily ring dose compared to film and gel and doesn’t account for trough 
concentrations in the FAME studies which were not measured; CVF, 5.7 (18.7) ng/mg, which is 
lower by 8- to 15-fold compared to our values, also consistent with formulation dose differences. 
Steady-state CVF DPV concentrations are 5 log10 greater than plasma and 1 log10 greater than 
cervical tissue, which is highly consistent with FAME 02 and FAME 02B given steady-state 
release of DPV from the ring and fluctuating concentrations with the film and gel. 
 
A cervical tissue DPV concentration-ex vivo explant challenge response relationship was 
demonstrated when controlling for participant as a covariate; in addition, participant specific 
differences in p24 production were identified. Product arm, however, was not statistically 
significant in this model, consistent with our simpler non-parametric comparisons. However, 
these data failed to fit traditional pharmacodynamic models, which we hoped would provide 
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useful IC50 concentrations. IC50 concentrations are useful in evaluating the comparability and 
appropriate scaling of ex vivo IC50 contrasted to in vivo IC50, which is essential to evaluate the 
clinical predictive value of such ex vivo tests. Lack of success with pharmacodynamic model 
fitting occurred due to too few concentrations above the LLOQ and, especially, a high degree of 
intra- and inter-participant variability. This was not, apparently, a limitation for the simpler linear 
model. For reference, the MTN-013 DPV vaginal ring and FAME 02 DPV film and gel also 
demonstrated a statistically significant linear relationship with a similar log-log transform of the 
variables. The consistent explant assay concentration-response seen in MTN-013, FAME 02, and 
FAME 02B indicates a clear dapivirine antiviral effect. There may also be a vehicle barrier effect 
contributing to this antiviral effect (as noted for some microbicide vehicles), but this cannot be 
determined for this product without a vehicle only control for comparison 54. 
 
In summary, we found no significant PK or PD differences between the DPV film and gel 
products. The PK findings were consistent with those found with one week of daily dosing 
(FAME 02), allowing for evidence of DPV accumulation in plasma, and dilution of CVL 
compared to CVF. Comparing both FAME studies (film and gel) with a 28-day DPV ring study 
(MTN-013), plasma and cervical tissue DPV concentrations were similar, accounting for steady-
state versus intermittent dosing differences. In addition, we demonstrated a linear concentration-
response relationship using ex vivo explant challenge when controlling for participant as 
covariate, despite a large degree of assay variability.  Especially in combination with the data 
from the companion FAME 02 study, which reported a high degree of acceptability and 
tolerability of the film product over one week of daily dosing, the film product may provide a 
more portable alternative to a DPV gel for women interested in periodic PrEP or who wish to 
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avoid an indwelling DPV vaginal ring. Effectiveness of any vaginal formulation of DPV awaits 
the outcome of randomized controlled clinical trials.  
 
 
2.6 Tables and Figures 
Table 2.1: Pharmacokinetic parameters of DPV in cervicovaginal fluid and cervical tissue 
homogenates after application of DPV film vs. gel 
 
Data for 168 hour not shown as all medians were below limit of assay quantitation (BLQ). 
ap=0.07 film v. gel (8 of 9 film > gel) 
bp<0.05 fornix vs. mid vagina 
cp<0.05 cervical os vs. fornix 
dp<0.05 mid vagina vs. cervical os 
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Figure 2.1: Dapivirine plasma and CVF concentration versus time for DPV film and gel 
 
Panel A indicates plasma dapivirine concentration. Open symbols (solid line) are film, closed 
symbols (dashed lines) are gel. BLQ values are arbitrarily displayed as 0 pg/mL. Panel B 
indicates cervicovaginal fluid and cervical tissue homogenate dapivirine concentrations in log10 
scale. Open symbols are film and closed are gel. Symbols represent mid vagina (round), 
posterior fornix (triangle), cervical os (square), and cervical tissue homogenate (diamond). 
Values are median with upper and lower quartiles. BLQ values are not shown; all medians at 168 








Figure 2.2: Cumulative HIV p24 antigen from ex vivo HIV challenge of cervical tissue explants 
after dosing with DPV film vs. gel 
 
 
Panel A indicates cumulative p24 antigen by false sequence categories for comparison. Each 
symbol-line pair is a unique research participant. Panel A1 presents cumulative p24 antigen at 
baseline (no drug) and after film dosing; panel A2 presents cumulative p24 antigen after gel 
dosing. Panel B indicates concentration-response relationship of cervical tissue homogenate 
dapivirine concentration (x-axis). No drug is open circle. Open triangles are film; closed 
triangles are gel. Upward pointing triangles are samples taken 5 hours after dosing; downward 



























































FAME 05 Study 
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While pre-exposure prophylaxis with oral tenofovir (TFV) disoproxil fumarate/emtricitabine 
reduces HIV acquisition rates, poor adherence to and acceptability of daily vaginal gels has led 
to development of vaginal film formulations to improve adherence and, potentially, enable 
episodic use.  
3.1.2 Study Design 
In this two-arm, cross-over study of a fast-dissolving tenofovir film (40 mg) compared to a 
previously studied semisolid tenofovir 1% gel (40 mg), 10 healthy women received a single 
vaginal dose of each study product. Clinical, pharmacokinetic, and antiviral assessments were 
performed over one week post-dose.  
3.1.3 Results 
Nine of 10 participants experienced mild to moderate adverse effects, similar between products, 
with no severe adverse events or events attributed to study products. TFV concentrations after 
film dosing exceeded concentrations after gel dosing in plasma between 8 and 24 hours (p<0.02). 
TFV concentrations in cervicovaginal fluid and both TFV and TFV diphosphate concentrations 
in cervical tissue homogenates were higher following film dosing (all p values < 0.04). The 
differences ranged from median (interquartile range) 2.9-fold (1.1, 9.0; midvaginal 
cervicovaginal fluid) to 4.4-fold (2.9, 7.7; plasma). Neither film nor gel demonstrated reduced 
cervical tissue biopsy infectivity after ex vivo HIV challenge.  
3.1.4 Conclusion 
Single dose tenofovir film demonstrated consistently higher concentrations in plasma and 
cervicovaginal samples when compared to gel during the first day following dosing. Single dose 
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cervical tissue TFV-DP concentrations at 5 hours exceeded steady-state concentrations 
previously reported with daily oral Truvada® dosing. Tenofovir film may provide an alternative 
to tenofovir gel formulations. Clinical efficacy remains to be tested. 
 
3.2 Introduction 
Human immunodeficiency virus (HIV) infection remains a global health problem with sexual 
intercourse being the most common mode of transmission.  Pre-exposure prophylaxis (PrEP) 
with tenofovir (TFV) containing regimens has proven effective in randomized controlled trials 
using daily oral tenofovir/emtricitabine. While effectiveness is best when product adherence is 
high 8,9,30-32, poor adherence may result in no protection, especially in women11,33,55. Responding 
to the negative PrEP impact of poor adherence, alternatives to daily oral dosing have been 
pursued including sustained release products that provide long-term protection with infrequent 
dosing and topical products potentially suitable for either episodic or sustained use35-37. Topical 
PrEP efficacy has been demonstrated with vaginal gel and ring formulations of tenofovir and 
dapivirine, though these have been only modestly effective11,23,30,47,55,56.  It is hoped that, similar 
to contraceptive product development where multiple formulation options lead to increased 
adherence and efficacy across the population, alternative PrEP formulations will boost overall 
adherence57.   
 
On-demand microbicide products may be preferred for persons at risk of HIV infection who 
desire PrEP, but struggle with daily oral dosing, prefer to avoid the potential for long-lasting 
toxicity from the systemic exposure of injectable formulations, or who only have occasional 
episodic HIV exposure risks not necessarily requiring long-term formulations. One such option 
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in development is fast-dissolving vaginal film formulations of dapivirine and TFV, which, in gel 
and intravaginal ring formulations, have proven PrEP efficacy11,23,30,55,56,58. Listerine® breath 
mint strips are one example of fast-dissolving film formulations on the market.  Among topical 
formulations, film may overcome limitations of the vaginal gel which include messiness; 
frequent leakage from the vagina after application; and product storage and transport 
complications due to the bulkiness of the applicator 48. By contrast, a vaginal film has: less 
volume to leak from the vagina or dilute innate endogenous antimicrobial factors in vaginal 
fluid; much smaller size for discreteness of use and portability; and less packaging to dispose of 
post-application. Vaginal films, like the nonoxynol 9 contraceptive film, have proven more 
desirable than other dosage formulations, including gels, tablets, and even vaginal rings49,50,59,60.   
 
Two prior studies have demonstrated the acceptability and pharmacokinetic (PK) equivalence of 
a fast-dissolving dapivirine vaginal film45,61. In this current study (FAME 05) we evaluated the 
single-dose, multi-compartment pharmacokinetics (blood, cervical tissue [CT], cervicovaginal 
fluid [CVF], and rectal fluid [RF]) and pharmacodynamics (PD, ex vivo HIV tissue explant 
challenge) of a fast-dissolving TFV film compared to the TFV 1% gel formulation used in prior 
clinical trials. A companion study, FAME 04, involved one week of daily dosing of the same 
TFV film and gel products with additional safety, immunological, and microbiome 
assessments62. 
 
3.3 Materials and Methods 
3.3.1 Study design and participants 
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This was a two-arm, single site randomized crossover study of two TFV formulations, conducted 
at the Drug Development Unit (DDU) of the Johns Hopkins Hospital in Baltimore, MD.  The 
protocol was approved by the Johns Hopkins Medicine Institutional Review Board 
(IRB00046617) and registered with Clinicaltrials.gov (NCT02280109). Ten healthy, HIV-
negative women between the ages of 18 and 45 years were recruited to participate. All 
participants provided informed consent prior to screening and study procedures. After a baseline 
evaluation to determine eligibility, each participant was randomized to one of two sequences of a 
single vaginal dose of one of two study products, either gel then film or film then gel. The study 
products were TFV 1% gel (a unit dose equivalent to 40 mg in 4 ml of gel) and tenofovir vaginal 
film (40 mg). The 2-by-2 inch TFV films were composed of hydroxypropyl methyl cellulose, 
hydroxyethylcellulose, sodium carboxymethylcellulose, and glycerin. 
 
At the first study visit after qualification, the investigational product was applied by a 
gynecologist during a pelvic exam. The TFV gel was applied using a polyethylene vaginal 
applicator (HTI Plastics, Lincoln, NE). The TFV film was placed, unfolded, in the midvagina 
during a speculum exam.  The participant remained recumbent for approximately 30 minutes 
after each dose. Participants returned for additional safety and PK sampling visits for the next 12 
hours and 24, 48, 72, and 168 hours after dosing. Serial blood samples were collected post-dose 
for plasma TFV concentration (0, 0.5, 1, 2, 4, 5, 8, 12, 24, 48, 72, and 168 hours) and peripheral 
blood mononuclear cell (PBMC) TFV diphosphate (TFV-DP) (0, 2, 4, 8, and 24 hours) 
concentrations. CVF samples from midvagina, external cervical os, and posterior vaginal fornix 
were collected at with a Dacron swab (Cardinal Health, McGraw Park, IL) 5, 72, and 168 hours 
after dosing. RF was collected at 5, 72, and 168 hours after dosing using an anoscope and Dacron 
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swab. At 5 and 72 hours after dosing, a pair of CT biopsies for PK and PD readouts were 
collected using Tischler forceps. 
 
Participants were seen on day 14 for a safety evaluation.   The second product was dosed during 
a similar point in a later menstrual cycle (avoiding menses) followed by the same sampling 
schedule.  A final set of cervical biopsies was collected at least two weeks after the second 
product dosing as negative control for the explant HIV challenge. 
 
3.3.2 Clinical assessment 
Participants were assessed for adverse events (AEs) at each study visit. AEs were graded based 
on the Division of AIDS (DAIDS) Table for Grading Adult and Pediatric Adverse Events, 
Version 1.0,(December 2004, Clarification dated August 2009) and the Female Genital Grading 
Table for Use in Microbicide Studies (Appendix 1 to DAIDS Table for Grading Adult and 
Pediatric Adverse Events, Version 1.0, December 2004, Clarification dated August 2009). 
 
3.3.3 Pharmacokinetic sample analysis 
TFV in plasma, CVF, RF , and CT biopsy homogenate as well as TFV-diphosphate (TFV-DP) 
concentrations in PBMC and CT homogenate were measured using ultra-performance liquid 
chromatographic-tandem mass spectrometric (LC-MS/MS) methods that have been previously 
described63,64. These methods were validated according to FDA Bioanalytical Method Validation 
Guidance65.  The lower limits of quantification (LLOQs) for these assays are: plasma TFV 0.31 
ng/mL, PBMC TFV-DP 50 fmol/sample or median 2 fmol/106 cells (based on number of cells 
analyzed), CVF TFV 0.625 ng/swab or median 0.005 ng/mg (based on swab weights), RF TFV 
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0.625 ng/swab or median 0.2 ng/mg (based on swab weights), CT TFV 0.05 ng/sample or 
median 0.003 ng/mg (based on biopsy weights), CT TFV-DP 50 fmol/sample or median 3 
fmol/mg (based on biopsy weights). 
 
3.3.4 Pharmacodynamic ex vivo HIV explant challenge 
As previously described, two CT biopsies were briefly exposed to HIV-1 BaL in the laboratory, 
and HIV infection was measured over the culture period by HIV-1 p24 ELISA assay (Alliance, 
Perkin Elmer) of culture supernatant (4, 7, 10, and 14 days after inoculation)66,67. The cumulative 
p24 antigen (sum of p24 antigen concentrations in explant culture supernatant), biopsy weight-
normalized and averaged for both biopsies at each time point was the unit of analysis. 
 
3.3.5 Data Analysis 
Concentration-time data and PK-PD relationships were visually examined (SigmaPlot, version 
13, Systat Software, San Jose, CA). Non-compartmental analysis of concentration data estimated 
PK parameters including peak concentration (Cmax), time to peak concentration (Tmax), area 
under the concentration-time curve to last sample (AUClast), and time to last concentration (Tlast)  
(Phoenix® WinNonlin® version 6.4, Certara USA, Inc., Princeton, NJ). Readouts were 
summarized using non-parametric descriptive statistics (median, interquartile range), the 
Friedman test for comparisons among readouts, the Wilcoxon rank sum test for paired 
comparisons, and the Spearman test for correlations between matrix concentrations (IBM SPSS 
Statistics v. 24, Armonk, NY). P values less than 0.05 were considered statistically significant. A 
PK-PD relationship was first assessed with linear regression of log transformed TFV and TFV-
DP concentrations in plasma, CT and CVF (each individually as single independent variables) 
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with log-transformed cumulative p24 concentrations (dependent variable) (IBM SPSS). Iterative 
model fitting using an Emax model (2 to 4 parameter Hill equation) with log-transformed PK and 




Ten women enrolled in the study, ranging in age from 22 to 45 years (median 33.5). Five women 
self-identified as African American, four as white (one as Hispanic/Latina), and one as Asian.  
All participants completed all study visits and evaluations. 
 
3.4.2 Adverse events 
Of 22 adverse events captured during the study, none were serious nor related to study product 
(Table 3.1). All resolved by the end of follow up.  Fourteen adverse events occurred after gel 
dosing, while 7 occurred after film dosing (p=0.20); one participant experienced an adverse 
event in the washout period between film and gel dosing. 
 
3.4.3 Pharmacokinetics 
Following dosing of each product, plasma TFV concentrations reached a peak between 1 and 12 
hours, then fell to undetectable concentrations (<0.31 ng/mL) by 48 hours in all but one 
participant (film 0.39 ng/mL and gel 0.51 ng/mL) (Figure 3.1). The time to peak concentration 
(Tmax) was later after film dosing, median (IQR) 8 hours (8, 8), when compared to gel dosing, 4 
(2, 8) (p=0.02). Peak concentrations (Cmax) of TFV were higher in 9 of 10 participants after film 
dosing, 10.4 ng/mL (3.9, 13.6), when compared to gel dosing, 2.9 ng/mL (1.5, 5.5) which 
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trended toward statistical significance (Table 3.2, p=0.08).  Plasma TFV concentration vs. time 
curves were similar before 8 hours, but separated (statistically significant) between 8 and 24 
hours after dosing, during which time concentrations following film dosing continued to rise and 
were greater by 3.1- to 4.4-fold when compared to individually-paired gel dosing (p<0.02). 
Overall, plasma TFV non-compartmental Cmax and AUClast were higher after film than gel dosing 
by 2.5-fold (1.8, 3.5) and 3.0-fold (2.6, 3.9), respectively (Table 3.2). Finally, the time until the 
last quantifiable concentration (Tlast) was later after film dosing, 24 hours (24, 24), when 
compared to gel dosing, 18 hours (12, 24), trending toward statistical significance (p=0.06). 
PBMC TFV-DP concentrations were below limits of assay quantification in all samples tested.  
 
CVF TFV concentrations sampled from all 3 intra-vaginal sites declined from 5 hours to 168 
hours after dosing, but remained detectable throughout the sampling interval (Figure 3.2).  Only 
1 of 10 participants had any CVF TFV concentration that was below the limits of assay 
quantitation (BLQ) 168 hours after dosing (exocervix, gel dosing). Mid-vagina CVF TFV Cmax 
and AUC (both p=0.014), as well as concentrations at all 3 sample times, were significantly 
higher after film compared to gel dosing (p<0.02) (Table 3.2). The differences ranged from 3.1-
fold (2.0, 3.8) higher at 168 hours to 4.4-fold (2.9, 7.7) higher at 24 hours. Forniceal CVF TFV 
trended toward higher concentrations after film than gel at 5 hours (p=0.08), but none of the 
exocervical CVF TFV concentrations differed between study products. When comparing among 
CVF sampling sites at any given time for the same product, forniceal samples were higher than 
exocervical samples, with a Cmax and AUClast forniceal:exocervical ratio of 2.0 (1.2, 6.8) and 2.0 
(1.2, 6.8), respectively (both p<0.01). Variability of samples (indicated by the range of quartiles) 
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was also greater for film compared to gel. CVF concentrations between sites were highly 
correlated (rho>0.94, p<0.001) 
 
TFV and TFV-DP concentrations in CT homogenates were also higher 5 hours after film dosing, 
28 ng/mg (7, 52) and 160 fmol/mg (27, 485), respectively, when compared to gel dosing, 8.7 
ng/mg (5.9, 14.0) and 40 fmol/mg (21, 93), respectively (both p<0.05). This resulted in paired 
film:gel ratios of 3.0 (1.1, 7.3) for TFV and 3.7 (2.0 17.8) for TFV-DP (p<0.04). Concentrations 
were not different 72 hours after dosing.  
 
Using molar concentrations of TFV and TFV-DP, the combined (film and gel) TFV-to-TFV-DP 
ratio in CT was 532 (332, 999) and not different between products. At 5 hours after dosing when 
all matrices were available and detectable, combined (film and gel) CVF tenofovir 
concentrations were 2 log10 and 5 log10 greater than tissue and plasma concentrations, 
respectively (p<0.001). CT TFV-DP correlated modestly with plasma TFV concentrations 
(rho=0.522, p<0.001) and correlated highly with both CVF (rho>0.818, p<0.001) and CT 
(rho=0.92, p<0.001) concentrations.  
 
Unlike TFV concentration and time differences (film greater than gel) at all other anatomic sites, 
RF TFV concentrations 5 hours after gel dosing were 12-fold (3, 39) greater than after film 
dosing (p=0.004). The RF concentration distribution 5 hours after gel, 2.5 ng/mg (0.5, 26), 
overlapped the 5 hour CT homogenate TFV concentration for both film, 31 ng/mg (11, 63), and 
gel, 9 ng/mg (6, 17). Time to peak RF concentrations were more common at 5 hours, but higher 
concentrations were seen 72 hours post-dose in 4 participants after film and one participant after 
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gel.  RF concentrations correlated least well of all matrices with all other matrices (rho <0.44, 
p>0.01). 
 
3.4.4 Pharmacodynamics (HIV-1 p24 measurement) 
Cumulative p24 antigen in the CT ex vivo HIV challenge assay was not different among values 
for baseline and both times (5 and 72 hours) for both film and gel formulations (p=0.4) (Figure 
3). Pairwise testing showed statistically significant differences only for the film formulation 
which increased between the 5 and 72 hour sampling times (p<0.01). Linear regression of 
cumulative P24 against drug concentrations (pooling concentrations for both film and gel dosing 
within each anatomic matrix) indicated no statistically significant PK-PD relationships (Figure 
3.4). Excluding baselines, any imputed values, or both did not result in any statistically 
significant regression slopes. Similarly, sigmoid Emax PK-PD modelling was not successful.  
 
3.5 Discussion 
We demonstrated the feasibility of a single dose TFV fast-dissolving film (40 mg) to achieve 
concentrations of TFV in plasma, CVF, and activated TFV-DP in CT which exceed those after a 
single dose of TFV 1% gel during the day of dosing; both film and gel had similar concentrations 
3 and 7 days later. Supported by the acceptability of the film established in the companion study, 
FAME 04, and the theoretical adherence advantages of films over other products, we believe this 
study helps to advance TFV film as a potentially viable product for extended safety and efficacy 




In contrast to FAME 04, a 7 dose study of the same film and gel, we report greater 
concentrations in all matrices (at some time points) after film compared to gel dosing. 
Temporally richer FAME 05 sampling (2, 4, 5, 8, and 12 hours) could detect the later peaking 
and higher 8-24 hour plasma TFV differences with film, which indirectly indicate differences in 
CVF and tissue TFV. Complementarily, FAME 04 was more analytically rich with readouts 
beyond PK and larger sample size. The other study difference was that the film was folded in 
half prior to dosing in FAME 04, whereas in FAME 05, the film was not folded. Folding can 
reduce the dissolution rate of the film.   
 
In addition, our FAME 05 concentrations in all matrices were below those in FAME 04. For 
example, our CT TFV-DP was 40 fmol/mg (20, 93) and 169 fmol/mg (84, 506) 5 hours after gel 
and film dosing, respectively, whereas, FAME 04 reported 222 fmol/mg (71, 556) and 937 
fmol/mg (56, 1456) 2 hours after dosing gel and film, respectively. Accumulation of drug with 
the 7 daily doses in FAME 04 compared to the single dose in FAME 05 explains this difference. 
Vaginal tissue concentrations rise even higher with longer daily dosing – 2,000 fmol/mg (4 
fmol/0.2 L) after 2 weeks reported by Schwartz, et al., and 1,807 fmol/mg (591, 5860) after 6 
weeks in MTN-001, both of which studies dosed the same TFV 1% gel daily68,69. Together, these 
studies indicate tissue accumulation continues through 2 weeks after which steady-state is 
achieved. Continuing accumulation of tissue TFV-DP for weeks of dosing is expected based on 
every 24 hour dosing and a longer cervicovaginal tissue TFV-DP half-life, 53 hours (45, 68); 
accordingly,  steady-state (6 half-lives) would require (IQR) 11 days to 17 days, consistent with 




Five hours after a single TFV film dose, CT TFV-DP concentrations easily exceeded vaginal 
tissue TFV-DP concentrations associated with daily oral TDF dosing (estimated from combined 
MTN-001 and HPTN 066, 23 fmol/mg [17, 25]) which occurs weeks after commencing daily 
oral dosing69,71. As concentrations with the first dose are even higher with film compared to gel 
in FAME 05, this evidence recommends advancing the film formulation for further clinical 
development. Development as a single episodic dose prior to HIV exposure might be considered, 
but depends on several key unknowns, namely, whether cervicovaginal tissue concentration of 
active drug is the single critical variable associated with PrEP efficacy and how long the 
concentration needs to be maintained.  
 
The evidence for the association between cervicovaginal tissue concentration and PrEP efficacy, 
however, remains indirect. In an analysis of seroconversion rates across the six primary daily 
dosing PrEP efficacy randomized clinical trials, using oral vs. vaginal tissue TFV-DP 
concentration-based differences provided a much tighter sigmoid Emax PK-PD model fit than 
systemic drug concentrations alone8,9,11,31-33,72. Possibly arguing against this, adherence 
adjustments in three TFV vaginal gel trials (CAPRISA 004, FACTS 001, VOICE) all 
demonstrated improved, but modest, efficacy in post hoc analyses11,30,47,55,56, despite estimates of 
higher tissue TFV-DP concentrations compared to oral dosing (discussed above). However, these 
PK-guided adherence adjustments were dichotomous adjustments into adherent and poorly 
adherent cohorts and lacked quantitative adherence benchmarks (similar to STRAND and HPTN 
066 for oral dosing) to fairly judge efficacy in highly adherent women71,73. Further, it remains 
unclear how long protective concentrations must be sustained after HIV exposure. While film 
achieves tissue TFV-DP concentrations in 5 hours that are 7-fold greater than estimated steady-
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state tissue concentrations associated with 90% protection in Partners PrEP (see below), the 
tissue TFV-DP concentration falls to 40% of the clinical tissue IC90 by 72 hours after the single 
dose and may need additional doses for protection in the episodic dosing setting.   
 
Due to the absence of clinical trial data to clearly indicate the TFV-DP concentration, anatomic 
site, and duration best predicting efficacy, viral challenge in animal models and ex vivo human 
tissue explants have been used as surrogates. Macaque models repeatedly demonstrate protection 
from SHIV and SIV vaginal challenge with prior TFV dosing74-78. We used the explant challenge 
in FAME 05, but failed to demonstrate an antiviral effect. By contrast, FAME 04 demonstrated 
an antiviral effect with CT TFV-DP IC90 of 813 fmol/mg. The difference in explant results may 
largely be explained by the fact that all, but one, of the single dose FAME 05 CT concentrations 
fell well below the explant IC90 in multiple dose FAME 04. Accordingly, there were too few 
high concentrations to generate a statistically significant downward slope.  
 
As with selecting tissue concentration targets, interpreting explant challenge model IC90 results 
doesn’t map directly to a clinical IC90. Consider, in MTN-001, participants demonstrated high 
adherence to prescribed daily TDF (indicated by median pre-dose TFV serum concentration of 
65 ng/mL), yet the vaginal tissue homogenate TFV-DP concentrations were below 25 fmol/mg69. 
With similar pre-dose serum TFV concentrations in one high adherence Partners PrEP cohort, 
>40 ng/mL serum TFV, the tissue TFV-DP concentrations are very likely similar79. This high 
adherence Partners PrEP subgroup had relative risk reduction of 89% for TDF only and 91% for 
TDF/FTC, approximating a clinical IC90
79. [This assumes no sex differences in efficacy that 
Partners PrEP wasn’t powered to detect.] By comparison, the explant IC90 reported in FAME 04 
 
 42 
is at least 1.5 log10 greater than the clinical IC90 from Partners estimated above. Similarly, the 
colon tissue explant IC90, 10,233 fmol/mg (RMP-02/MTN-006), is 1.7 to 2.5 log10 greater than 
the clinical IC90 for colon tissue TFV-DP estimated in iPrEx
8,73,80,81. [The iPrEx clinical IC90 is 
based on 90% efficacy associated with 2 to 4 doses per week based on the STRAND study; in 
HPTN 066, 2 to 4 doses per week achieved colon tissue homogenate TFV-DP concentrations 
from 27 to 186 fmol/mg8,71,73.] Accordingly, both the cervicovaginal and colon explant challenge 
models appear too stringent and need recalibration to estimate the likelihood of clinical 
protection. In addition, as discussed above, whether the calibration for oral TDF (often 
complicated by concomitant dosing with emtricitabine) is relevant for topical TFV remains to be 
demonstrated and will require an efficacy trial.  
 
Concluding, we demonstrated that a single dose of TFV 40 mg film achieved higher and more 
sustained concentrations in plasma, CVF, and CT compared to TFV 1% (40 mg) gel. Further, CT 
TFV-DP concentrations exceed tissue concentrations associated with high levels of protection 
with oral dosing, though the comparability of tissue protective concentrations and timing after 
oral compared to topical dosing has not been established. With its single dose advantages 
compared to TFV gel, and several theoretical advantages of films over gels which may favorably 
impact adherence, the film formulation remains a promising vaginal microbicide candidate. 
Longer duration safety and efficacy studies are needed to establish the anticipated adherence 
advantage and, possibly, superior efficacy of the TFV film formulation relative to gel.  
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3.6 Tables and Figures 
Figure 3.1: Plasma TFV vs. time by product (median [IQR]). Nominal sampling times offset for 
clarity. 
 
Figure 3.2: Cervicovaginal and rectal fluid, cervical tissue homogenate TFV concentrations vs. 




Figure 3.3: Explant ex vivo HIV challenge over time by product. 
 
Control (no drug) biopsy is indicated as “BL” (baseline), for comparison, even though the biopsy 




Figure 3.4: Cumulative P24 Antigen v. TFV Concentration across all matrices by product. 
Regression lines are not shown since no linear regression fitting demonstrated statistically 
significant slopes (none different from slope=0). Baseline values arbitrarily imputed as 0.01 units 
in each panel. Concentration values below the lower limit of assay quantitation (LLOQ) are 











Systemic 2, nasal congestion, fatigue 1, upper respiratory infection 
Chemistry 0 4, hyperglycemia (non-fasting) (N=3), 
elevated AST 
Hematology 3, anemia (2 Gr 2) 2, anemia 
Urinalysis  0 1, hematuria 
Gastrointestinal  1, constipation 3, nausea, heartburn, diarrhea (N=2) 
Neurologic 1, headache 2, headache 2 
Gynecological 
Pain 
0 1, dysmenorrhea 
 
Nine of 10 research participants reported total 22 adverse events, 21 during dosing period which 
are indicated. None were attributed to study product. No Grade 3 or 4 events were reported. All 
grade 1, except hematology (3 Grade 2 in parentheses). No differences in adverse event number 
when comparing Film to Gel (Wilcoxon, P=0.20). Initial number indicates number of 
participants experiencing the adverse event; if multiple symptoms are included in a category, the 
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0.004 - - - - 
BLQ, below lower limits of assay quantitation 
Cmax units: TFV, plasma ng/mL, CVF ng/mg, RF ng/mg, CT ng/mg; TFV-DP fmol/mg 
AUC units: TFV, plasma ng-hr/mL, CVF ng-hr/mg, RF ng-hr/mg, CT ng-hr/mg; TFV-DP fmol-hr/mg 







CHAPTER 4: Conclusion 
Determining how an investigational product delivers a drug to relevant target tissues, and how 
the movement of the drug through the body correlates with intended or unintended effects, are 
crucial initial steps in the process of drug development. The two studies presented in this thesis 
illustrate the importance of pairing pharmacokinetic and pharmacodynamic investigations in 
order to best inform the design of larger clinical efficacy trials.  
 
4.1 Vaginal Microbicides for HIV Pre-Exposure Prophylaxis 
FAME 02b and FAME 05 provided similar types of data regarding four candidate vaginal 
microbicides: dapivirine gel and film (FAME 02b) and tenofovir gel and film (FAME 05). 
FAME 02b demonstrated that dapivirine was safe and well tolerated when applied vaginally in 
both film and gel formulations. There were no statistically significant differences in dapivirine 
concentrations across anatomic sampling sites between the two formulations, although the film 
trended towards a higher dapivirine CVF concentration in the midvagina compared to either the 
vaginal fornix or cervical os. The half-life of dapivirine was significantly longer in plasma 
compared to cervical tissue. The cervical tissue explant assay demonstrated reduced HIV p24 
production with both dapivirine gel and film at 5 hours after dosing, although there were no 
differences found between the two study products. 
 
FAME 05 demonstrated a similar safety profile for tenofovir vaginal gel and film. Plasma 
tenofovir concentrations peaked sooner after product application than dapivirine and fell to 
undetectable levels by 48 hours after dosing in most participants. In contrast, dapivirine was 





were equally well tolerated, they were found to have divergent pharmacokinetics. Tenofovir film 
led to higher plasma Cmax and AUClast compared to gel, a difference which was statistically 
significant between 8 and 24 hours after dosing. The film product also led to higher TFV and 
TFV-DP concentrations compared to gel in CVF and cervical tissue. Only rectal fluid TFV 
concentrations were higher following gel dosing compared to film, but correlation of these 
concentrations with the other tissue matrices was poor. There was no difference in HIV p24 
production in the cervical tissue explant challenge between products, nor was there any 
difference between baseline biopsies and after either film or gel dosing. 
 
Based on these two studies, dapivirine and tenofovir vaginal gel and film are promising products 
to help women prevent HIV infection.  The pericoital dosing of films and gels may be more 
acceptable to some women than use of a daily PrEP product. Larger randomized clinical trials of 
both types of products should be pursued to demonstrate effectiveness. 
 
4.2 Challenges 
The development of PrEP for prevention of HIV infection has been fraught with setbacks. Early 
studies of oral PrEP regimens involving TFV alone or in combination with emtricitabine found a 
44-75% decrease in HIV acquisition8,82. Subsequent studies yielded disappointing results with 
oral PrEP no more effective at reducing HIV acquisition than placebo10,11.  A closer look at the 
data from these more recent studies showed a clear relationship between product adherence and 
efficacy. Among women who adhered most closely to the recommended dosing regimen in the 
VOICE trials, there was significant protection against HIV acquisition11.  Unfortunately, only 





adherence. Adherence based on detectable drug concentration was similarly low in FEM-PrEP 
(15-37%)10, and somewhat better in FACTS 001 (64%)13. 
 
A similar pattern was seen in studies of early vaginal microbicides. CAPRISA 004 found a 39% 
decreased risk of HIV acquisition among women who used pericoital vaginal TFV gel12.  The 
pericoital regimen involved administering a dose of TFV vaginal gel prior to and after penile-
vaginal intercourse, with no more than 2 doses in a 24-hour period. Despite these early 
promising results, larger trials showed no benefit to vaginal TFV gel11,13. 
 
Subgroup analyses in large studies of oral PrEP and vaginal microbicides found reduced rates of 
HIV infection among participants whose plasma drug concentrations were consistent with 
greater product adherence. While it makes empiric sense that greater use of oral or vaginal PrEP 
would lead to improved protection against HIV, there remains the possibility of additional 
confounding factors. There was no analogous way to objectively assess adherence to placebo 
products – there was no ingredient that could be measured in blood or vaginal fluid to confirm 
whether women assigned to placebo products used them consistently. It is possible that women 
with highest levels of microbicide and PrEP adherence experience different risk of HIV infection 
compared to women with lower adherence.  If the behavior of high product adherence is 
associated with less behavioral risk of HIV, this may partly account for the protection attributed 
to oral or vaginal PrEP.  More consistent use of pericoital TFV gel in the FACTS 001 trial was 
associated with lower HIV incidence regardless of treatment group (HR 0.48, 95% CI 0.26-0.89), 
which suggests the behavior of greater adherence may itself be protective13. Without a way to 






In an attempt to understand why self-reported product adherence was so much higher than 
adherence based on objective measures (i.e. plasma drug concentrations) in the VOICE trial, a 
qualitative study was performed among a subset of participants83. Several reasons for over-
reporting product use were elicited, and participants identified receiving real-time feedback and 
drug concentration monitoring as a way to improve adherence.  The logistics of obtaining plasma 
or CVF drug concentration data in a relevant time for providing this real-time feedback are 
difficult, but this is one strategy that could strengthen future studies so that the true efficacy of 
PrEP products can be determined. 
 
4.3 Future Directions 
The development of products that a woman can use to reduce her risk of HIV infection without 
needing the permission of a male partner has been identified as an important part of improving 
HIV prevention. Daily oral PrEP has been shown to be effective when taken consistently, but 
poor adherence in several studies suggest that this one intervention will not work for all people. 
An analogy can be drawn with the different types of female contraception. Daily birth control 
pills are highly effective at preventing pregnancy when they are taken correctly and consistently, 
but many women have difficulty maintaining the high level of compliance needed for maximum 
efficacy84. This in part led to the development of multiple non-daily, non-oral contraceptive 
options including a monthly vaginal ring, 3 month injectable, and longer-acting implants and 
intrauterine devices that are effective for 3 to 10 years. There are also pericoital contraceptives 
such as a diaphragm or vaginal spermicides for women who prefer to use these products only 





multiple effective products, as one strategy will not meet the needs of all potential users. It is 
likely that each individual woman may have varying needs throughout her life, making a daily 
oral preventive strategy preferable sometimes and an as-needed vaginal preventive product 
preferable at other times. Having multiple HIV prevention products will allow women to switch 
between products, or even combine them for greater protection. As vaginal film and gel products 
are further developed, it will be important to investigate their compatibility with male and female 
condoms, and to consider whether the protection provided by vaginal microbicides is equivalent 
to the protection provided by oral PrEP. If the level of protection is similar across products, 
women could choose to use oral PrEP sometimes and vaginal microbicides at other times, 
depending on their individual circumstances. 
 
Vaginal microbicides will likely only protect women from exposure that occurs via penile-
vaginal intercourse.  As demonstrated in this thesis, systemic drug concentrations are achievable 
following vaginal microbicide dosing, but the systemic drug concentrations are not likely to 
provide protection from HIV infection in distant sites. For women who have sex with men, the 
primary route of HIV transmission is through receptive vaginal intercourse, with the vaginal 
mucosa being the most likely site of HIV infection. Measuring drug concentrations in vaginal 
mucosa is logistically more complicated than measuring drug concentrations in other, more 
accessible compartments (i.e. blood, cervicovaginal fluid, cervicovaginal lavage).  It is likely that 
vaginal tissue drug concentrations will be more variable in larger studies when the relationship 
between product dosing and tissue sample collection is less well defined. Variations in adherence 
will also increase the variability in tissue drug concentrations. Small studies with more intensive 





describe relationships among drug concentrations across these varied compartments and to 
clarify what drug concentration in vaginal tissue is protective.  
 
One question that remains to be answered is whether the use of a vaginally applied microbicide 
will protect against HIV exposure via heterosexual RAI. FAME 05 demonstrated that tenofovir 
is detectable in rectal fluid after application of both film and gel products, but it is unclear what 
level of protection is achieved in the rectum. The prevalence of RAI among heterosexual women 
is lower than vaginal intercourse, but the risk of HIV exposure is greater85. There are currently 
several studies investigating rectal microbicides to protect against HIV transmission that occurs 
during RAI. A full description of these products is beyond the scope of this document. 
 
4.3 Conclusion 
Stopping the spread of HIV will require multiple types of interventions, including increasing 
access to antiretroviral treatment, minimizing maternal to child transmission, and preventing new 
infections from occurring. Vaginal microbicides such as the gels and films described in this 
thesis offer a non-daily prevention strategy that may be more acceptable to some women than 
daily oral PrEP.  Additional clinical trials of vaginal films and gels are needed to determine 
product efficacy on a larger scale. Randomized clinical trials of similar vaginal PrEP products to 
date have been plagued by poor adherence despite rigorous participant education and support 
during the studies10,11,13.  Future studies would be enhanced by including objective measures of 
adherence and real-time feedback to study participants. Having multiple ways to prevent HIV 
infection is likely to increase use overall and will hopefully achieve population level decrease in 





lives – having options that can meet different needs for the same individual or couple is 





APPENDIX A: FAME 02b Study Documents 
 Study Protocol 





FAME 02b Study Protocol  
A.1 Objectives 
A.1.1 Primary Objective: 
To compare the levels of dapivirine in the cervicovaginal fluid, genital tissue, and blood samples 
using single dose gel and film formulations of dapivirine microbicide. 
A.1.2. Secondary Objectives:   
 To compare the effect of single dose dapivirine gel or film formulation on cervical tissue 
explant challenge with HIV. 
 To compare the safety of single dose dapivirine gel and film formulations 
A.2 Study Design 
A.2.1 Identification of Study design 
This is a single site, randomized open-label crossover study. Five subjects will receive the 
treatment sequence of gel followed by film. Five other subjects will receive the treatment 
sequence of film followed by gel. 
A.2.2 Description of Study Population 
The study population will be HIV uninfected women who meet criteria as outlined in section 5. 
A.2.3 Time to Complete Accrual 
This project will take 3 months to accrue and 6 months to complete. 
A.2.4 Study Groups 
Subjects will receive dapivirine gel verses dapivirine film in a crossover design in a randomized 
sequence. 
A.2.5 Site  






A.3 Study Population 
A.3.1 Selection of Study Population 
The inclusion and exclusion criteria in this section will be utilized to ensure the appropriate 
selection of study participants.  
A.3.2 Recruitment 
Participants will be recruited from a variety of sources. Participants will also be referred to the 
study from other local research projects.  Recruitment materials will be approved by the Johns 
Hopkins Institutional Review Board 
A.3.3 Retention 
Once a participant is enrolled, the study site will make every effort to retain her in follow-up to 
minimize possible bias associated with loss-to-follow-up. The site will implement the following 
procedures to enhance retention: 
 Thorough explanation of the study visit schedule and procedural requirements during the 
informed consent process and re-emphasis at each study visit.      
 Thorough explanation of the importance of completing participation to the overall 
success of the study. 
 Collection of detailed locator information at the study screening visits, and active review 
and updating of this information at each subsequent visit. 
 Use of appropriate and timely visit reminder mechanisms. 
 Immediate follow-up on missed visits. 
A.3.4 Inclusion criteria: 





2. HIV negative by EIA within 28 days of enrollment (Appendix 1). Note: Only EIA non-
reactive subjects will be enrolled. Individuals testing positive by EIA will be excluded, 
but confirmatory testing and referral for follow-up will be determined by the testing 
algorithm conducted by the Johns Hopkins Hospital Clinical Laboratory. 
3. Understand and agree to local STI reporting requirements. 
4. Able and willing to provide written informed consent to take part in the study. 
5. Able and willing to provide adequate information for locator purposes. 
6. Availability to return for all study visits, barring unforeseen circumstances. 
7. Availability to return for the second formulation dosing at the same time in the subject’s 
menstrual cycle as when the first formulation was administered, at least 10 days before 
menses. 
8. Willing to abstain from vaginal intercourse and insertion of anything (e.g., drug, vaginal 
douche, or sex toy) in vagina for 72 hours before each study product exposure, and 7 days 
following each vaginal sampling procedure. 
9. Willingness to have partner(s) use condoms (must not contain Nonoxynol-9) for the 
duration of the study. 
10. Agree not to participate in other research studies involving drugs and/or medical devices. 
11. Negative qualitative urine pregnancy test. 
12. Per participant report, using an effective method of contraception at enrollment; 
hormonal method (except vaginal ring) used continuously for the past 30 days; 
intrauterine device (IUD [copper or hormonal] inserted at least 30 days prior to 
enrollment); female sterilization; abstinent from sexual activity with male partner for the 





effective method of contraception until the completion of final scheduled study visit if 
enrolled. 
13. Willingness to remain in the research unit for up to 24 hours on each of two dosing days,  
A.3.5 Exclusion criteria:  
1. Current sexual partner known by participant to be HIV seropositive. 
2. Individuals who, by history, engage in condom-less intercourse with HIV-infected 
partners, or partners that have unknown HIV serostatus, or women who exchange sex for 
money, shelter, or gifts. 
3. Active sexually transmitted infection or documented treatment of sexually transmitted 
infections including, but not limited to: chlamydia, gonorrhea, syphilis, trichomonas, 
cervicitis or PID within 6 months prior to enrollment. 
4. Known history of genital HSV (diagnosed by either clinical or laboratory test).  
5. Symptomatic vaginal candidiasis or bacterial vaginosis. 
6. Undiagnosed irregular uterine bleeding 
7. Pathology of the female genital tract, which in the judgment of the investigator might 
increase the risk of the study to the research participant. 
8. Individuals who are status post hysterectomy. 
9. History of any cervicovaginal procedure (i.e. colposcopy with cervical biopsy) within the 
past 2 months.  Individuals who have a history of cone biopsy or extensive loop 
electrosurgical excision procedure (LEEP), which in the judgment of the investigator may 
affect permeability assessment. 
10. Any known primary or secondary uro-genital malformations, which in the assessment of 





11. Use of vaginally administered medications within 4 week of enrollment 
12. Any active urinary tract infection 
13. By history, subjects with irregular menstrual cycles. 
14. At screening: 
a. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 
1.5 X the site laboratory ULN (upper limit of normal) 
b. Hemoglobin less than 10.0 g/dL 
c. Platelet count less than 100,000/mm3 
d. Other safety tests outside of the normal range that in the judgment of the 
investigator may interfere with conduct of the study. 
e. Positive findings on urinalysis that are clinically significant in the opinion of the 
investigator 
15. Estimated creatinine clearance < 60 ml/min based on established nomograms 
16. Recent history (past 6 months) of injection drug use or, a level of alcohol use that, in the 
judgement of the Investigator of Record, may interfere with the conduct of this study. 
17. Unwillingness to refrain from aspirin and NSAIDs product use for one week prior to and 
one week post study procedures. 
18. Use of warfarin or heparin. 
19. Use of systemic immunomodulatory medications within 4 weeks of enrollment. 
20. Use of product containing nonoxynol-9 within 4 weeks of enrollment. 
21. Use of any investigational products within 4 weeks of enrollment. 
22. Any other medical conditions deemed not safe for participation by the investigator. 





24. Post-menopausal defined as 12 months of amenorrhea. 
       
A.4 Study Product 
A.4.1 Regimen: 
Subjects will be randomized to receive one of the two following sequences: 
 Single dose of Dapivirine gel 4759 (0.05% w/w dapivirine, in 2.5 grams of gel—total 
dapivirine content, 1.25 mg per dose),  followed by single dose Dapivirine film (1.25 
mg/film) 
 Single dose of Dapivirine film (1.25mg/film) followed by single dose Dapivirine gel 
4759 (0.05% dapivirine, 2.5 g/ 3.4 mL volume)   
A.4.2 Administration 
A study clinician will administer the product with the aid of a speculum for consistency of 
placement in the region between the mid vagina and anterior fornix.   
A.4.3 Study Product Formulation 
Dapivirine Film: Dapivirine film was formulated in a polyvinyl alcohol (PVA) based vaginal 
film containing hydroxypropyl methyl cellulose (HPMC) 4000 cp, polyethylene glycol 8000 
(PEG), propylene glycol, and glycerin. PVA constituted 38.3% (w/w) of the film. The target 
loading dose for the film is 1.25 mg dapivirine per film.  
Dapivirine Gel 4759:  Dapivirine gel 4759 (0.05%) is formulated as a hydrophilic semi-solid 
(gel) for vaginal administration. The excipients in the drug product formula are pharmacopoeia 
grade components that have a history of use in currently approved vaginal products. Each pre-
filled applicator will contain approximately 2.5 g of dapivirine 0.05% gel. Dapivirine gel 4759 





A.4.4 Study Product Supply and Accountability 
IPM is the IND holder for dapivirine and will ensure that packaged Dapivirine gel 4759 study 
product is provided to the Johns Hopkins Investigational Drug Service (IDS) pharmacy.  The 
University of Pittsburgh Magee Women’s Research Institute (MWRI) will provide the dapivirine 
film product to the IDS. All study products will be available to the study staff through the IDS 
Pharmacy. 
The IDS staff will maintain complete records of all study products received for this protocol and 
dispensed to participants.  These records will not be available to other members of the research 
staff.  Additional documentation will be required for study gel returns, destruction (if applicable) 
and other related issues as outlined in instructions for DAIDS clinical trials. All unused study 
products must be returned to the Pharmacy after the study is completed or terminated.   
A.4.5 Study Product Dispensing 
Study products will be dispensed only to enrolled participants upon receipt of a written 
prescription signed by an authorized prescriber.   
A.4.6 Concomitant Medications 
Enrolled study participants may use concomitant medications during study participation.  All 
concomitant medications, over-the-counter preparations, vitamins and nutritional supplements, 










Table A.1. Schedule of Events  
Event Screen 
Formulation Dose #1 F/U 
#1 
Formulation Dose #2 F/U 
#2 
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 
Post-Dose hours  
 0-
12 






24  48  72  168  
Informed Consent X             
History & Physical X             
Safety labs X   X  X X   X  X X 
STI screening1 X             
Qualitative HCG X X4     X X4     X 
Urinalysis X   ▲  ▲ X   ▲  ▲ X 
Vital Signs X X X X X X X X X X X X X 
AE Assessment X X X X X X X X X X X X X 
Symptom Directed 
Exam 
 X X X X X X X X X X X X 
Dose Product #1  X            
Dose Product #2        X      
PK Plasma 2  X X X X X  X X X X X  
Rectal Fluid3  X   X X  X   X X  
Cervicovaginal 
fluid3 
 X   X X  X   X X  
 3              
Cervical Biopsy3  X   X   X   X   
Subject 
Instructions 
 X X X X X  X X X X X  
HIV-1/2 ELISA X      X      X 
▲ = If clinically indicated 
(1)  STI screening will consist of NAAT testing for gonorrhea, chlamydia, trichomonas, as well 
as serologic screening for syphilis using syphilis treponemal testing. 
(2)  Blood PK plasma collection will be obtained at pre-dose, 0.5, 1, 2, 4, 5, 8 and 12 hours (Day 
0), 24 hours (Day 1); 48 hours (Day 2); 72 hours (Day 3); and 168 hours (Day 7) following 
dapivirine formulation dosing. The time points for specimen collections are approximate. 
Windows will be +/- 5 minutes for 0-12h hours, +/- 1 hour for the period 24-72 hours, +/- one 
day for 168 hours. 
(3)  Rectal Fluid collection, cervicovaginal fluid sampling, and cervicovaginal biopsy will be 
performed 5 hours (+/- 1 hour) and 72 hours following dapivirine formulation dosing. Rectal and 
Cervicovaginal fluid will also be collected at 168 hours post-dosing. 
(4)  Qualitative urine pregnancy tests will be performed within 24 hours prior to dosing 
 
All participants will be counseled to avoid the use of spermicide and other non-study vaginal 
products (other than tampons during menstruation and female condoms) while participating in 





alternative methods, but reported use of these products does not require any change in study 
product administration or follow-up procedures. Vaginal douching will be prohibited for the ten 
days following dosing with a dapivirine formulation. Condoms provided by study staff will not 
be coated with any type of spermicide.   
 
A.5 Study Procedures 
This section describes visit-specific study procedures.    
A.5.1 Visit 1: Screening Visit (within 30 days prior to Formulation #1 Dosing) 
All subjects will undergo screening procedures prior to enrollment in the protocol. Screening 
procedures may occur over several visits. Informed consent will be obtained at screening, prior 
to the procedures listed in Table 7 above.  This will be done by an interactive question and 
answer process where the potential subject will be asked specific questions to determine her 
understanding of the purpose, procedures, risks and benefits in participating in the trial.  If in the 
judgment of the investigator the subject cannot demonstrate sufficient understanding, then that 
subject will be excluded from participation in the protocol.    
Screening procedures will include: 
 Complete history and general physical examination to determine eligibility for the study.   
 Complete GYN examination including collection of swabs 
 One cervical swab: to test for gonorrhea, chlamydia, and trichomoniasis. 
 Phlebotomy to obtain blood for pregnancy test, complete metabolic panel and complete 
blood count, HIV antibody testing. 
 Urinalysis to rule out urinary tract infection.   





 Assessment for adverse events that occur over the screening period. 
 Subjects will be advised to abstain from vaginal intercourse, vaginal products, vaginal 
douche or vaginal insertion of sex toys at least 72 hours  prior to dosing of formulation # 
1 and formulation #2, and 7 days following each biopsy (with the exception of study 
dosings and procedures) 
 Pregnancy testing will be repeated prior to administration of formulation #1. 
Subjects who meet the inclusion and exclusion criteria following the Screening Visit will be 
enrolled and randomized to a formulation sequence (gel-film or film-gel). As part of scheduling, 
care will be taken to attempt scheduling the visit at a time when the participant is not expecting 
to be actively bleeding or anticipating her menses within 10 days.  
Subjects with active vaginal bleeding at the dosing visit will not be randomized/enrolled at that 
time.  Subjects found to have vaginal bleeding on pelvic exam may be rescheduled if vaginal 
bleeding resolves before 30 days from Screening have elapsed. If vaginal bleeding does not 
resolve during the window period, and the subject expresses interest in enrollment for the study, 
she may be offered a rescreening attempt. 
A.5.2 Visits 2 & 8: Formulation Dosing Visits 
The dose formulation will be vaginally administered by a study clinician.  
Study procedures and follow-up will then proceed as outlined in the Schedule of Events.: 
Dosing Visit Hour-by-Hour (same for gel and film) 
Day 0 (within 30 days of all screening evaluations)  
 Subject arrives at the research unit 
 Urine pregnancy test performed, required negative to continue with dose. 





 Symptom-directed exam will be performed. 
 Assessment for adverse events as noted from the history, and physical examination and as 
defined in section 9.3. 
-1 hour 
 Insert saline lock for PK’s 
 Pre-dose blood collection for drug concentration assessment.  
0 hour 
 Dose dapivirine formulation. 
 Begin blood collections for drug concentration  
o Plasma at following times: 0, 0.5, 1, 2, 4, 5, 8, 12 hours after dosing. The saline 
lock will be removed following the 12 hour pharmacokinetic timepoint. 
5 hours (+/- 1 hour) 
 Cervicovaginal samples (fluid sampling with an absorptive device from mid-vagina, 
fornices, exocervix,) and cervical biopsies (three biopsies for homogenate drug 
concentration and explant challenge) are being collected. 
 Rectal fluid collection 
During each study visit, participants will be queried for adverse events and counseled to avoid 
the use of spermicide and other non-study vaginal products (other than tampons during 
menstruation and female condoms) while participating in the study.   
24 hours (Visits 3 and 9) 
 Blood collection for dapivirine plasma.  
 Vital signs will be obtained. 





 Symptom-directed physical exam, if needed. 
 Subject instructions including counseling to avoid the use of spermicide and other non-
study vaginal products (other than tampons during menstruation and female condoms) 
while participating on the study.  Subjects will be counseled to abstain from sexual 
intercourse and all other insertive vaginal practices for 10 days following each 
administered dose (or 7 days after the last cervicovaginal sampling at 72 hours). 
48 hours (Visits 4 and 10) 
 Blood collection for Complete Metabolic Panel, Complete Blood Count, urinalysis (if 
clinically indicated) and dapivirine plasma concentrations.  
 Vital signs will be obtained. 
 Assessment for adverse events. 
 Symptom-directed physical exam, if needed. 
 Subject instructions including counseling to avoid the use of spermicide and other non-
study vaginal products (other than tampons during menstruation and female condoms) 
while participating on the study.  Subjects will be counseled to abstain from sexual 
intercourse and all other insertive vaginal practices for 10 days following each 
administered dose (or 7 days after the last cervicovaginal sampling at 72 hours). 
72 hours (Visits 5 and 11) 
 Blood collection for dapivirine plasma concentrations.  
 Vital signs will be obtained. 
 Assessment for adverse events. 





 Cervicovaginal samples (vaginal fluid sampling from mid-vagina, fornices, exocervix,) 
and cervical biopsy (three biopsies for tissue drug concentrations and explant challenge) 
are being collected. 
 Rectal fluid collection 
 Subject instructions including counseling to avoid the use of spermicide and other non-
study vaginal products (other than tampons during menstruation and female condoms) 
while participating on the study.  Subjects will be counseled to abstain from sexual 
intercourse and all other insertive vaginal practices for 10 days following each 
administered dose (or 7 days after the last cervicovaginal sampling at 72 hours). 
168 hours (Visits 6 and 12) 
 Blood collection for dapivirine plasma. 
 Vital signs will be obtained. 
 Assessment for adverse events. 
 Symptom-directed physical exam, if needed. 
 Cervicovaginal fluid (vaginal fluid sampling from mid-vagina, fornices, exocervix,), 10. 
 Rectal fluid collection. 
 Safety labs, including a complete metabolic panel and complete blood count and a 
urinalysis (if clinically indicated). 
 Subject instructions including counseling to avoid the use of spermicide and other non-
study vaginal products (other than tampons during menstruation and female condoms) 
while participating on the study.  Subjects will be counseled to abstain from sexual 
intercourse and all other insertive vaginal practices for 10 days following each 





A.5.3 Visits 7 & 13. Two Week Post-Dose Follow-up Visit 
Subjects will return to the research clinic at Day 14 (Visit 7) to assess their state of health post-
study. This evaluation will include a symptom-directed examination and vital signs will be 
obtained. Safety labs, including a complete metabolic panel, complete blood count, urinalysis, 
HIV antibody testing, and a qualitative urine pregnancy test will be performed.   
Subjects are released to home with a scheduled Dosing Visit (Visit #8) appointment planned to 
coincide within one week of the time in the menstrual cycle associated with the first dosing visit.  
The first Follow-up Visit (visit 7) should follow the first Dosing Visit at 14 days (+ 2 days). The 
final Follow-up Visit (Visit 13) will occur 14 days (+2 days) after Dosing Visit #2 (Visit 8). The 
events for the second Follow-up visit (Visit #13) are the same as for the first Follow-up Visit 
(Visit 7). 
A.5.4 Clinical Evaluations and Procedures 
Physical exams will include the following assessments:   
Vital signs: 




 Weight (at Screening only) 
 Height (at Screening only) 
Clinical assessments of: 
 Complete history and physical examination a screening 









 Menstrual  
Additional assessments may be performed at the discretion of the examining clinician in 
response to symptoms or illnesses present at the time of the exam. 
A.5.5 Laboratory evaluation 
 Urine pregnancy test 
 Urinalysis, if clinically indicated 
 GC/CT/Trichomonas Nucleic Acid Amplification Test 
 Syphilis Chemiluminescence Assay 
 HIV antibody testing (ELISA) 




o Carbon Dioxide 
o Glucose 
o Urea Nitrogen (BUN) 
o Creatinine 
o Calcium 






o Total Bilirubin 
o Alkaline Phosphatase 
o AST 
o ALT 









 Dapivirine drug levels in cervical tissue, cervicovaginal fluid, rectal fluid, and plasma  
A.5.6 Specimen Collection and Processing 
Since samples from up to 6 compartments will be collected, standardized protocols will be 
established for sample collection, isolation of mucosal mononuclear cells from tissue (above), 
cell separation and counting. 
The site will adhere to the standards of good clinical laboratory practice and site standard 
operating procedures for proper collection, processing, labeling, handling, transport, and storage 
of specimens.  In cases where safety laboratory results are not available due to administrative or 






A.5.7 Biohazard Containment 
As the transmission of HIV and other blood-borne pathogens can occur through contact with 
contaminated needles, blood, and blood products, appropriate blood and secretion precautions 
will be employed by all personnel in the drawing of blood and shipping and handling of all 
specimens for this study as recommended by the CDC and NIH.  All biological specimens to the 
Hopkins University lab will be transported using packaging mandated by CFR 42 Part 72.  
Biohazardous waste will be contained according to institutional, transportation/carrier, and all 
other applicable regulations 
 
A.6 Assessment of Safety and Clinical Management 
A.6.1 Safety Monitoring 
The study site investigators are responsible for continuous close safety monitoring of all study 
participants, and for alerting the Protocol Team if unexpected concerns arise. A sub-group of the 
Protocol Team, including the Protocol Chair or designee, the DAIDS Medical Officer, the IPM 
Medical Officer, and the External Safety Monitor will serve as the Protocol Safety Review Team 
(PSRT). Close cooperation among the PSRT and the study site will be necessary to monitor 
participant safety and respond to occurrences of toxicity in a timely manner. Appropriate safety 
monitoring will be contingent upon excellent communication between study participants and 
study staff, and upon cooperation among study staff, investigators, the External Safety Monitor, 
IPM Medical Officer, and the DAIDS Medical Officers  





An External Safety Monitor who is familiar with the pertinent scientific literature related to the 
study product will be responsible for the first review of data and safety monitoring.  This 
physician, independent of the study sponsor, will be available to monitor data from this site.  
His/her minimum qualifications will include experience as a physician and experience in the 
conduct of clinical research. This individual will not receive salary or other support from the 
grant. The External (Independent) Safety Monitor model has been used successfully for other 
Johns Hopkins HIV Microbicide studies involving investigational products. The proposed 
individual will meet the qualifications outlined above and have training in the importance of the 
objective treatment of clinical safety data.   
The Data Management team for this site will generate data summaries for the External Safety 
Monitor, the DAIDS Medical Officers and IPM Medical Officer on a monthly basis. These data 
summaries will include adverse event, type, grade and association with the study products, 
accrual and retention data. The External Safety Monitor will evaluate adverse event data 
independently as well to determine whether or not the study protocol should continue as 
originally designed, should be changed, or should be terminated.   
Approximately once a month the PSRT will convene via telephone to review adverse event data. 
If more urgent safety matters arise, these calls can occur more frequently.   
The IRB will be notified of any serious and unexpected adverse events according to the policies 
of the Johns Hopkins Medicine IRB. 
The following information will be submitted to the IRB at the time of renewal of a research 
protocol, as required by the IRB guidelines: 






 A summary of any assessment performed to evaluate external factors or other relevant 
information that may have an impact on the safety of study volunteers or the ethics of the 
research study; 
 A summary of the outcome of procedural reviews conducted to ensure subject privacy 
and research data confidentiality; 
 Any conclusions regarding changes to the anticipated benefit-to-risk ratio of study 
participation and final recommendations related to continuing, changing, or terminating 
the study, with accompanying rationales as appropriate. 
A.6.3 Adverse Events Definitions 
An AE is defined as any untoward medical occurrence in a clinical research participant 
administered an investigational product and which does not necessarily have a causal 
relationship with the investigational product.  As such, an AE can be an unfavorable or 
unintended sign (including an abnormal laboratory finding, for example), symptom or disease 
temporally associated with the use of an investigational product, whether or not considered 
related to the product.  This definition is applied to all groups beginning from the time of 
randomization.  The term “investigational product” for this study refers to both the gel and the 
film, as well as the study gel applicator. 
Study participants will be provided instructions for contacting the study site to report any 
untoward medical occurrences they may experience, except for possible life-threatening events, 
for which they are instructed to seek immediate emergency care.  Where feasible and medically 
appropriate, participants will be encouraged to seek evaluation at Johns Hopkins Hospital, where 
the study clinicians are based, and to request that a study clinician be contacted upon their 





study medical providers related to untoward medical occurrences will be obtained for review. All 
participants reporting an untoward medical occurrence will be followed clinically until the 
occurrence resolves (returns to baseline) or stabilizes over a four week period. 
Study site staff will document in source documents all AEs reported by or observed in enrolled 
study participants regardless of severity and presumed relationship to study product.   
For each study participant, AE documentation and reporting will be undertaken throughout the 
scheduled duration of follow-up.  
The PI/designee will grade the severity of each AE and the relationship of the AE to study 
product:   
 AE severity will be graded per the DAIDS Table for Grading Adult and Pediatric 
Adverse Events, Version 1.0, December 2004 and the Female Genital Grading Table for 
Use in Microbicide Studies (Appendix 1 to the DAIDS Table for Grading Adult and 
Pediatric Adverse Events, Version 1.0, December 2004), except that asymptomatic BV  
will not be considered an AE. AEs not included in the Female Genital Grading Table will 
be graded by the DAIDS AE Grading Table Version 1.0, December 2004.  In cases where 
a genital AE is covered in both tables, the Female Genital Grading Table for Use in 
Microbicide Studies will be the grading scale utilized.   
 The relationship of all AEs reported on CRFs will be assessed based on the Manual for 
Expedited Reporting of Adverse Events to DAIDS, the Investigators Brochures, and the 
clinical judgment of the PI/designee.  The study products that must be considered when 







The DAIDS Table for Grading Adult and Pediatric Adverse Events, the Female Genital Grading 
Table for Use in Microbicide Studies, and Version 2.0 of the Manual for Expedited Reporting of 
Adverse Events to DAIDS are available on the DAIDS Regulatory Compliance Center (RCC) 
web site:   http://rsc.tech-res.com/ 
All AEs will be captured on an AE log form.  The form should be reviewed at each study visit 
and updated as needed.  For any serious or expedited AEs (SAEs/EAEs) that are continuing at a 
participant’s study exit visit, the PI/designee must establish a clinically appropriate follow-up 
plan for the AE and review with the DAIDS Medical Officers.  At a minimum, the AE must be 
re-assessed by study staff at least 2 weeks after the participant’s study exit visit; additional 
evaluations also may take place at the discretion of the PI/designee.  The same approach must be 
taken for any AEs deemed related to study product that are found to have increased in severity at 
the study exit visit.  For those AEs requiring re-assessment, if the AE has not resolved or 
stabilized at the time of re-assessment, study staff will continue to re-assess the participant at 
least once per month while the study is ongoing.  After the study has ended, all AEs requiring re-
assessment will be re-assessed at least once within the 30-60 days after the study end date.   
A.6.4 Expedited Adverse Event Reporting Requirements 
Expedited Adverse Event Reporting to DAIDS 
Requirements, definitions and methods for expedited reporting of Adverse Events (AEs) are 
outlined in Version 2.0 of the DAIDS EAE Manual, which is available on the RSC website at 
http://rsc.tech-res.com/safetyandpharmacovigilance/. The DAIDS Adverse Experience Reporting 
System (DAERS), an internet-based reporting system, must be used for expedited AE reporting 
to DAIDS. In the event of system outages or technical difficulties, expedited AEs may be 





EAE reporting procedures specific to this protocol are that once the site has submitted EAEs via 
DAERS (as above), the RSC Safety Office will also prepare the draft safety reports and send 
them to IPM and DAIDS Medical Officers for review. The study site will be contacted by the 
DAIDS Medical Officer if any further information or clarification is needed after the report is 
evaluated by IPM and DAIDS Medical Officers. The RSC Safety Office will then prepare the 
final report which will go to IPM for signature and submission to the FDA. Copies of this final 
report will be filed with IPM and RSC. Additionally, the RSC Safety Office will distribute safety 
reports to all DAIDS sites that use products under investigation in this study. 
For all EAEs submitted, sites must file an RSC update with the final or stable outcome unless the 
initial EAE submitted had a final or stable outcome noted already. 
EAE Reporting Level 
This study uses SAE category of expedited AE reporting as defined in the DAIDS EAE Manual.   
Study Agents for Expedited Reporting to DAIDS 
The study agents that must be considered in determining relationships of AEs requiring 
expedited reporting to DAIDS are:  dapivirine gel, dapivirine film, and the study gel applicator.   
Reporting Period 
AEs must be reported on an expedited basis during the entire study duration for an individual 
subject (from study enrollment until study completion or discontinuation of the subject from 
study participation for any reason). 
Participants Who Become Pregnant 
Urine pregnancy tests will be performed during the investigational protocol. Participants who 
become pregnant in follow-up will be referred for obstetric care. The participant will be 





complete metabolic panel and complete blood count. Pelvic exams will only be performed to 
evaluate a participant's reported symptom. No genital specimens will be collected in a pregnant 
participant. Staff will continue follow-up contact with the participant to obtain pregnancy 
outcome data 
Of note, the participant will be encouraged to continue in the study so that safety data might be 
collected.  
A.6.5 Clinical Management of Adverse Events   
By definition, an adverse event can be either a new finding or symptom or a worsening of a pre-
existing condition. In order to accurately capture adverse events in follow-up, a thorough 
baseline history will be obtained at Visit 1 and Visit 2.  For example, for participants who 
endorse a history of headache, site staff will probe for and record details surrounding the 
condition such as frequency, location, duration, medication use, triggers, etc. Only by eliciting a 
full description will study staff be equipped to determine whether a subsequent event in follow-
up is a clinically distinct event or not. 
Adverse events will be elicited during the safety contact telephone call and in-clinic follow-up 
visits. Referral to appropriate care will be offered to participants as needed. Vaginally applied 
medications should not be used if possible.  
A.6.5.1 Product Hold 
In the unlikely event that a participant is intolerant of the study product immediately after 
placement, the site clinician will perform a pelvic exam to remove all visible product. Product 
will be permanently discontinued for this participant. If a participant experiences a grade 1 or 2 
adverse event following product use, site investigators have the discretion to hold any subsequent 





be held at investigator discretion until the condition resolves and/or the investigator deems it safe 
to resume product use. If a participant experiences a grade 3 or 4 event following product dosing, 
the site will temporarily hold any subsequent study product dosings, notify the PSRT, and await 
its recommendation regarding further product dosing. Participants who discontinue study product 
will be encouraged to remain in the study for follow up evaluations for safety. With the 
exception of pregnancy and HIV seroconversion, as outlined in Section 8.4 above, since these 
are single dose administrations of study product formulations, the study team will attempt to 
complete all evaluations associated with that dosing formulation according to the study protocol, 
so long as there is no increased risk for the study participant. 
A.6.6 Criteria for Early Termination of Study Participation 
Participants may voluntarily withdraw from the study for any reason at any time. Participants 
will be withdrawn from the study if they test positive for HIV antibody, or become pregnant 
during the study. Any participant who tests positive for HIV while enrolled in the study will be 
immediately removed from the study and referred to the appropriate care provider for additional 
counseling and treatment as necessary. No additional doses of study drug will be given. Patients 
who become pregnant will not receive additional doses of study drug, and will be discontinued 
from the study, as described in Section 8.4. Pregnancy outcomes will be collected for all study 
participants by contacting these women soon after anticipated parturition. After the participant’s 
final study contact, any pregnancy outcomes that meet criteria for SAE reporting as described 
above (e.g., congenital anomalies) occurring among participants will continue to be 
expeditiously reported.  
The Site PI/designee also may withdraw participants from the study to protect their safety and/or 





be withdrawn if the study sponsors, government or regulatory authorities, including the Office of 
Human Research Protections (OHRP), or site IRBs/ECs terminate the study prior to its planned 
end date.  Every reasonable effort is made to complete a final evaluation of participants who 
withdraw or are withdrawn from the study prior to completing follow-up.  Study staff members 
will record the reason(s) for all withdrawals in participants’ study records. 
 
A.7 Statistical Considerations 
A.7.1 Review of Study Design 
The primary aim of this study is to directly compare data among women receiving active 
microbicide in the form of a water-based gel, the delivery method most widely used in 
microbicide research currently, and novel thin film formulations of the microbicide. Urogenital, 
systemic and menstrual symptoms will be collected via symptom review with participants.  
Testing for sexually transmitted infections will occur at the screening visit to rule out other 
potential causes of reproductive tract inflammation and epithelial disruption.    Pharmacokinetic 
measures will assess local and systemic absorption of dapivirine following single exposure.   
A.7.2 Sample Size and Accrual 
Sample size of 10 will allow us to exclude differences as large as 1.2 standard deviation units 
relative to the mean when comparing film to gel results with 80% power and 5% 2-sided Type I 
error. In our experience with these intensive PK designs, this sample size has been more than 
adequate to the exploratory nature of these studies. Research participants without complete key 
data, for whatever reason, may be replaced. Key data includes plasma, cervical biopsies, and 





Research participants will be recruited from among prior research participants in similar types of 
studies. Accrual is expected to take 3 months to accrue and 6 months to complete.   
A.7.3 Study Endpoints 
Primary Endpoint 
Pharmacokinetic (PK) 
 Systemic absorption of dapivirine 
o Systemic absorption of dapivirine will be determined following exposure as 
detected in plasma sample as outlined the study SOP’s.   
 Local absorption of dapivirine 
o Local absorption of dapivirine will be determined following exposure as detected 
in genital tissue biopsy samples as outlined the study SOP’s.   
 Persistence of dapivirine in cervicovaginal and rectal fluid 
o Persistence of dapivirine will be determined as detected levels of dapivirine in 
cervicovaginal and rectal fluid collected as outlined in the study SOPs.   
Secondary Endpoints 
Pharmacodynamic (PD) 
 Ex vivo explant challenge with HIV 
o Cervical tissue will be challenged ex vivo with HIV and supernatant aliquots will 
be sampled over 14 days to determine p24 antigen concentration. 
Safety 






Complete concealment of allocation will not be feasible in this study.  Participants and study 
staff will not be blinded to drug formulation.   
A.7.5 Random Assignments 
Johns Hopkins IDS will prepare a randomization sequence (either gel, then film or film, then gel) 
for subjects and dispense product according to that schedule. - 
A.7.6 Data Monitoring and Analysis 
A.7.6.1 Data Monitoring 
This clinical trial will be conducted in compliance with the protocol, GCP guidelines, and 
applicable regulatory requirements.  All research charts are maintained in a double locked room. 
The research staff, under the direction of the primary investigator, will create and maintain an 
electronic database on the computers in the Drug Development Unit research offices. The 
database will be backed up every night onto the appropriate server’s back-up system.  
Appropriate firewall and virus scanning software are installed and updated routinely by the 
information technology staff. 
Case report forms will be used as the first point of data entry for this protocol. Study data 
management staff will manually review the forms for completeness and accuracy.  If queries or 
discrepancies are noted, the staff person will speak with the clinician in question as soon as 
possible to resolve the problem. The investigator will review the case report forms for 
completeness and accuracy at the end of the study.  
A.7.6.2 Safety Assessment 
Safety endpoints will be determined using all history, physical, and laboratory data prior to and 
following each of the product doses. The number of adverse events in each treatment will be 





percent, and 95% confidence intervals. Individual participants will contribute once to the 
calculation of event rates. Differences in the proportion of participants experiencing adverse 
events among the treatment arms will be compared using Fisher’s exact tests. However, this 
Phase I study may not have an adequate sample size to detect significant differences between 
treatment arms. 
A.7.6.3 Analysis of PK Data 
Blood levels of dapivirine will be evaluated after vaginal administration. PK parameters for 
plasma and PBMC DPV will be estimated (e.g., Cmax, Tmax, AUC, elimination rate constant) 
using WinNonlin (Pharsight, Inc., Cary, NC). All PK parameters for plasma and PBMC as well 
as paired assessments of other matrices will be compared between formulations using a multi-
level analysis (STATA/IC 11.2 for Windows software, StataCorp LP, College Station, TX) to 
assess formulation, sequence, and individual effects.   
A.7.6.4 Analysis of PD data 
HIV explant challenge will be assessed using cumulative HIV p24 measured in culture media 
supernatant. These values will be compared between formulations using a multi-level analysis to 
assess product, sequence, and subject effects. Concentration-response relationships will be 
evaluated for PK-PD data using sigmoid Emax modeling among other pharmacometric methods 
(WinNonlin, Pharsight, Inc. Cary, NC). 
 
A.8 Human Subject Considerations 
The investigators will make efforts to minimize risks of these products to human subjects.  
Volunteers will take part in a thorough informed consent process throughout their participation 





the protocol will have been submitted to the FDA.  The investigators will permit audits by the 
NIH or the FDA or any of their appointed agents. 
A.8.1 Special Populations 
Study staff will offer screening to eligible women of all ethnic and racial groups.  Members of 
the study staff are not seeking the screening or enrollment of women in special or vulnerable 
populations.  The following section also discusses special considerations for male partners of 
participants. 
Men  
Men are not included as subjects in the study because the study is testing a vaginal application of 
the study product.  The male sexual partners of women participating in this study will not be 
consented or monitored for because protocol-specified guidelines for abstinence and condom use 
are expected to protect male partners from exposure to the study product.  In addition, based on 
both preclinical and clinical data, no toxicity is anticipated from the study product.   
Children 
The NIH has mandated that children be included in research trials when appropriate.  This study 
will enroll women aged 18 and above who are able to give informed consent.  This study meets 
“Justifications for Exclusion” criteria for children as set forth by the NIH.  Specifically, "the 
research topic to be studied is irrelevant to (young) children" and "a separate, age-specific study 
in (adolescent) children is warranted and preferable" at a later time86 . 
Prisoners 
Prisoners will not be included in this study (for screening or enrollment).  Any participants 
incarcerated during the course of participation in the trial will not be followed during their 





from incarceration will be permitted to return for any protocol specified follow-up or safety visits 
per the guidelines of the local IRB. 
Pregnant women 
Pregnancy is an exclusion criterion because there are no current recommendations for the use of 
dapivirine during pregnancy.  Prior to administration of study product, a urine pregnancy test 
will be performed on all women. During the informed consent process, women will be informed 
that dapivirine is not known to prevent pregnancy and that the effect of dapivirine on a 
developing human fetus is unknown.  All potential participants will be required to use a reliable 
method of contraception as outlined in the Inclusion Criteria. Women who become pregnant 
during the study period following randomization and exposure to study product will not be 
excluded from analysis. Subjects will be followed during and after pregnancy to determine 
outcomes. 
A.8.2 Informed Consent Process 
Written informed consent will be obtained from all potential study participants prior to the 
initiation of any study-related procedures.  The informed consent process will give individuals all 
of the relevant information they need in order to decide whether to participate, or to continue 
participation, in this study.  Potential research participants will be encouraged to ask questions 
and to exchange information freely with the study team.  Only listed research staff may obtain 
informed consent from potential study participants.  The investigators will keep research 
participants fully informed of any new information that could affect their willingness to continue 
study participation.   






It is not expected that this trial will expose human subjects to unreasonable risk.   
In previous studies involving dapivirine gel and placebo, the following side effects were noted in 
women exposed to dapivirine but not to placebo: genital itch, vaginal pain, dysuria, vaginal 
erythema, loose stools, bloated abdomen, neutropenia, vaginal candidiasis, elevated alanine 
aminotransferase, elevated aspartate aminotransferase, elevated bilirubin, uterine spasm, breast 
discomfort, cervical erythema, genital herpes, malaise, somnolence, stomach discomfort, and 
vomiting.  Common side effects for both active study group and placebo group participants 
included headache and metrorrhagia. Serious adverse events that have occurred in clinical trials 
with dapivirine gel (but considered to be unrelated to gel use) include hospitalization for a 
diabetic foot, severe headache, gastritis, thrombotic thrombocytopenic purpura, abdominal 
abscess, and uterine leiomyoma 40,42.  
Cervicovaginal lavage has been associated with mild discomfort secondary to the introduction of 
sterile fluid into the vagina and its removal.  Collection of genital tissue by biopsy may cause 
discomfort and spotting.  On rare occasions, chemical cauterization and or suturing may be 
required if hemorrhaging occurs.  Phlebotomy or the intravenous catheter may lead to discomfort 
which may persist for the duration of the indwelling lock, feelings of dizziness or faintness, 
and/or bruising, swelling and/or infection. 
Disclosure of sexually transmitted infection (STI) may cause sadness or depression in volunteers.  
Disclosure of HIV-positive status has been associated with depression, suicidal ideation, and 
denial as well as social isolation.  Participation in clinical research includes the risks of loss of 
confidentiality and discomfort with personal nature of questions. Confinement to the clinical 






A.8.4 Minimization of risks 
To minimize the risk of a product being dosed to the wrong subject, study personnel will confirm 
the IDS dispensed drug with the study subject identity, per hospital protocol.  The clinical 
investigation sheet checklist will be signed off in real time to assure there is no redundant 
sampling outside the requirements of sampling called for by randomization. 
A.8.5 Benefits 
This is a no benefit study. The participant may appreciate the opportunity to contribute to the 
body of knowledge in the field of microbicide research.  
A.8.6 Incentives 
Volunteers will not be charged for any of the study visits, study supplies or examinations.  There 
are no costs to participants in this study, including overnight housing and transport provided by 
the study team.  Using the Johns Hopkins Drug Development unit remuneration schedule, 
women will be compensated for their time and inconvenience while participating in the protocol. 
This remuneration schedule is based on standardized payments related to the study visits and 
study-specific procedures.  
A.8.7 Participant Confidentiality 
Members of the study staff are all trained in patient confidentiality.  The log of study subject 
names and other protected health information is kept in a double locked area.  All computer 
information about study volunteers is kept on a computer with log-on passwords.    The data 
management and clinical staff are the only personnel with access to the protected health 
information of study volunteers.  Each member of the staff has log-on identification and 
password, logs off before leaving a computer screen unattended, and closes their office door 





Hopkins School of Medicine network, which is redundantly firewalled against penetration from 
the outside. Study-specific files are accessible only to staff of the Division of Clinical 
Pharmacology via a password-protected server. All research records will be kept for a minimum 
of five years following closure of this study.    
A.8.8 Communicable Disease Reporting 
Study staff members will comply with all local requirements to report communicable diseases 
including chlamydia, gonorrhea, syphilis, and HIV identified among study participants to the 
Baltimore City Health Department.  Study team members will include discussion of mandated 
reporting during the study informed consent process. 
A.8.9 Access to HIV-Related Care 
The investigators do not expect a screening population at high risk for HIV infection.  However, 
trained clinical staff will refer subjects who test positive or indeterminate via the HIV antibody 
screen test to a physician for follow-up testing and care.  Participants who have positive or 
indeterminate results will have standard post-test counseling as well as limited follow-up 
confirmatory testing provided by the study. Only study staff trained and experienced in HIV pre-
test and post-test counseling and who are investigators on this study will provide these study 
procedures.  Approved written materials consistent with the local clinical standard of care will 
support pre-test and post-test counseling.  Various local resources are available for medical care 
for HIV positive patients, including the Moore Clinic at Johns Hopkins University.  Subjects will 
be offered referral information from among a list of resources (as outlined in SOP #DDU-C-044-
07, Attachment 4).  Subjects will also be offered Maryland Community Services Locator referral 
information.  In addition to referral information, subjects will be provided with information for 





Hopkins Hospital Patient Information handout, “HIV Human Immunodeficiency Virus,” per 
Johns Hopkins medicine policy.  
A.8.10 Study Discontinuation 
NIAID, the International Partnership for Microbicides, the US FDA, other government or 
regulatory authorities, or the Johns Hopkins Medicine Institutional Review Board may 
discontinue this study at any time.  Ongoing safety monitoring will track the incidence of AEs 
and EAEs.  In the event of an abnormal number of reported AEs and/or EAEs judged to be 
related to study gel or applicator, or any other condition deemed as an emergency event by the 
study staff, the External Safety Monitor will contact the Principal Investigator to initiate a 
temporary hold on further enrollment. 
 
A.9 Laboratory Specimens and Biohazard Containment 
A.9.1 Laboratory Specimens 
Laboratory specimens will be handled in a manner consistent with institutional, OSHA, and GLP 
guidelines.  Study staff members are trained in the appropriate handling of laboratory specimens.  
Samples such as urine that will be divided for multiple analyses will be divided according to site 
SOP. 
Table A2: Designated Labs for Testing 





JHH Clinical Laboratory 
 





Nucleic Acid Amplification 
test 
JHH Clinical Laboratory 







Rectal fluid Dapivirine CPAL 
(non-diagnostic laboratory) 
Baltimore, MD 
Blood Complete Metabolic Panel 
Complete Blood Count 
HIV antibody screen 
(Appendix I) 
Syphilis Chemiluminesence 
assay (with confirmatory RPR; 
FTAABS performed on RPR 
negative samples) 




Dapivirine concentration CPAL 
(non-diagnostic laboratory) 
Baltimore, MD 
Cervical Biopsy HIV explant challenge CPAL 
(non-diagnostic laboratory) 
Baltimore, MD 
*CPAL, Clinical Pharmacology Analytical Laboratory, Division of Clinical Pharmacology, 
Johns Hopkins University 
A.9.2 Urine Samples 
A urinalysis will be used to screen for possible urinary tract infection when clinically indicated.  
Urine will be tested for qualitative HCG.  
A.9.3 Cervical Samples 
Biopsies to measure dapivirine drug concentrations and tissue explant susceptibility to HIV 
infection. 
A.9.4 Cervical Swabs 
C. trachomatis, N. gonorrhoeae, and trichomonas will be detected using an amplified DNA 
assay.   
A.9.5 Cervicovaginal Fluid sampling 
Obtained to measure dapivirine concentration. 





Obtained to measure dapivirine concentration.   
A.9.7 Plasma Samples 
Plasma samples will be sent to the Hopkins CPAL for assay of dapivirine concentration. 
A.9.8 Quality Control and Quality Assurance Procedures 
The Johns Hopkins Drug Development Unit and CPAL have a wealth of experience from taking 
part in several clinical studies of microbicides. Thus, all testing done in this research laboratory 
is performed with the same level of quality control as required in a licensed clinical laboratory.  
Because all of the proposed studies to be conducted in this project will be using an 
investigational product, the studies will be conducted under IND and additional measures will be 
undertaken to ensure that all protocols will be conducted under good laboratory practice.   
A.9.9 Specimen Storage and Possible Future Research Testing 
Participants will be consented for future use of vaginal and cervical specimens and blood 
samples.  Any leftover samples will be stored at CPAL for an indefinite period of time.  The 
principal investigator will assume primary responsibility for control of this area. 
Any results from research done on leftover specimens will not be placed in health records and 
will be kept confidential.  Informed consent will give participants the option to withdraw their 
consent for use of their specimens for future research.  The language and format employed in the 
screening and enrollment consents for these purposes are an IRB-approved means commonly 
employed in studies performed at this and other study sites within our institution to obtain 
permission for use of stored samples.  All primary study endpoints, protocol-specified testing, 
and QA/QC testing will be ascertained prior to any additional testing of stored specimens.  When 
all laboratory assays have been completed and the study has been closed, the PI for the study will 





who chose to have their samples destroyed at the end of the study.  These samples will be 
discarded in the appropriate manner and the disposition will be documented. 
A.9.10 Biohazard Containment 
Biohazardous waste will be contained according to institutional and all other applicable 
regulations. 
 
A.10 Administrative Procedures 
The study proposal for funding, this protocol, the informed consent document, data collection 
forms, and advertising flyers are all reviewed by the Johns Hopkins School of Medicine 
Institutional Review Board prior to enrollment of participants in the study. 
A.10.1 Study Coordination 
Study implementation will follow this protocol, which may not be amended without prior written 
approval from the Sponsor and DAIDS Medical Officer.  Close coordination between protocol 
team members is necessary to track study progress, respond to queries about proper study 
implementation, and address other issues in a timely manner.  Rates of accrual, retention, follow-
up, and AE incidence will be monitored closely by the team. 
A.10.2 Study Monitoring 
Site monitoring visits will be conducted to assess overall study compliance, as required per 
Requirements for On-Site Monitoring of DAIDS Funded and/or Sponsored Clinical Trials, GCP, 
and FDA regulations 21 CFR Part 312:  
http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/onsitemon
itor_reqs.pdf  





 Assess compliance with the study protocol, Good Clinical Practices (GCP) guidelines, 
and applicable regulatory requirements, including US CFR Title 45 Part 46 and Title 21 
Parts 50, 56, and 312 
 Review informed consent forms, procedures, and documentation 
 Perform source document verification to ensure the accuracy and completeness of study 
data 
 Verify proper collection and storage of biological specimens 
 Verify proper storage, dispensing, and accountability for investigational study products 
 Assess implementation and documentation of internal site quality management 
procedures 
 Assess site staff training needs 
Site investigators will allow study monitors to inspect study facilities and documentation (e.g., 
informed consent forms, clinic and laboratory records, other source documents, case report 
forms), as well as observe the performance of study procedures.  Investigators also will allow 
inspection of all study-related documentation by authorized representatives of the DAIDS, 
Sponsor and US regulatory authorities.  A site visit log will be maintained at the study sites to 
document all visits. The outcomes of the monitoring visits and the subsequent reports of 
resolutions of any identified problems will be provided to the Sponsor of the IND application. 
A.10.3 Protocol Compliance 
Amendments to the protocol will require prior written approval from the principal investigators.   
All protocol amendments will be submitted for DAIDS review and approval facilitated by the 
DAIDS Regulatory Support Center (RSC). Once approval has been provided by the RSC, such 





for final review and approval.  Once the Johns Hopkins Medicine IRB has given final approval, 
the amendment can be implemented. 
A.10.4 Investigator’s Records 
The investigator will maintain, and store securely, complete, accurate and current study records 
throughout the study.  Study records will not be destroyed prior to receiving approval for record 
destruction from DAIDS.  Applicable records include source documents, site registration 
documents and reports, correspondence, informed consent forms, and notations of all contacts 
with the participant.   
A.10.5 Use of Information and Publications 
Publication of study results will be governed by DAIDS policies.  The investigators will submit 
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4. What are the risks or discomforts of the study? 
Risks of blood draws:  Blood drawing may cause discomfort.  You may feel dizzy or faint, or develop a 
bruise, swelling or infections where the needle is inserted.  The total amount of blood collected during 
the entire study is less than 1 cup (about 13 tablespoons) 
 
Risks of pelvic (GYN) exam and cervicovaginal fluid sampling:  During pelvic exams and the 
cervicovaginal fluid sampling, you may feel discomfort or pressure in your vagina and/or pelvis.  From 
the pelvic exam you may also have vaginal bleeding or spotting. 
 
Risk of rectal sponge sampling: When rectal fluid is collected via insertion of the plastic tube into the 
anus, on rare occasion you may experience mild discomfort  or have pain (should you have another condition 
that is already causing pain in the area)  
 
Risks from STD Testing:  You may become embarrassed, worried, or anxious when receiving STD 
counseling.  You also may become worried or anxious while waiting for your test results or after 
receiving positive test results.  It may also cause sadness or depression.  HIV positive results have been 
associated with depression, suicidal thoughts, denial, and social isolation.  Trained counselors will be 
available to help you deal with these feelings.  Although the study site will make every effort to protect 
your privacy and confidentiality, it is possible that your involvement in the study could become known 
to others, and that social harms may result (i.e., because you could become known as “high risk” for 
HIV infection).  For example, you could be treated unfairly or discriminated against, or could have 
problems being accepted by your family and/or community.  In addition to referring you to treatment 
services, we can refer you to health or mental health services if you wish.  However, Johns Hopkins and 
the NIH do not have funds to pay for treatment once you are referred. 
 
By law, positive results from some STD tests have to be reported to local health authorities.  This 
reporting may result in a potential loss of confidentiality. 
 
Risks from intravenous (IV) catheters:  Risks include pain from the needle stick, bruising, and 
bleeding, but these are usually mild. Sometimes a person can feel dizzy or faint when the IV catheter is 
being inserted. Other risks include infection, damage to the vein, blood clot, or st roke (if air enters the 
vein), but these are rare. 
 
Risks from cervical biopsies:  You may feel slight to moderate pain at the time of the biopsy (like 
being pinched) which usually resolves quickly, but could last a few hours.  You may have spotting 
(small amounts of vaginal bleeding) for 1 – 2 days. There is a small risk of the biopsy area becoming 
infected or having bleeding that is heavier than spotting.  It is important for you to know your body is 
healing for 24-48 hours after the biopsy is collected.  However, if you have bleeding heavier than your 
usual menstrual period, notice a foul odor or a heavier vaginal discharge (more than usual), you should 
contact the study clinic right away. To ensure that the biopsy sites heal, we will ask you to avoid vaginal 
intercourse and putting anything into your vagina (such as tampon, sex toy) for 7 days after the biopsy is 
collected (10 days after receiving the study product). 
 
Risks from study gel and film:  The study products can cause some side effects.  We do not yet know 
all the side effects of the film.  Some, but not all women who used gel in other studies have had 
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Risks from the study drug:   
The study drug has been compared with placebo in other research studies. A placebo is a substance that 
looks like the study drug but that  contains no active ingredients. Common side effects reported by 
participants receiving placebo or dapivirine were headache and spotting.    
 
Based on side effects reported among women in previous studies, dapivirine vaginal product may be 
associated with genital itching, vaginal pain, painful urination, vaginal redness, loose stools, bloated 
abdomen, low white blood cell count, yeast infection, elevated liver enzymes, uterine spasm, breast 
discomfort, cervical redness, genital herpes, malaise (uneasiness or generalized discomfort), tiredness, 
stomach discomfort and vomiting.   
 
Serious side effects reported during dapivirine trials that are thought to be unrelated to dapivirine gel 
include hospitalization for diabetic foot, severe headache, gastritis, thrombotic thrombocytopenic 
purpura (a condition where blood clots form in the blood vessels), abdominal abscess (infection in the 
belly), and uterine fibroids. 
 
There may be side effects and discomforts that are not yet known.   
 
5. Are there risks related to pregnancy? 
Pregnant women cannot take part in this study.  There are no current recommendations for the use of 
dapivirine during pregnancy.  Dapivirine is not known to prevent pregnancy and the effect of dapivirine 
on the developing human fetus is unknown.  In order to reduce these risks, you will be tested to 
determine if you are pregnant at the beginning of the study and this test  will be repeated the day you 
receive the dapivirine gel or film.  If any of these tests show that you are pregnant, you will not be 
allowed to continue in the study.  It is important for you to let the study doctor know if you become 
pregnant or suspect that you are pregnant while taking part in this study. 
 
This research may hurt an embryo or fetus in ways we do not currently know.  
 
6. Are there benefits to being in the study? 
There is no direct benefit to you from being in this study. If you take part in this study, you may help 
others in the future. 
 
7. What are your options if you do not want to be in the study? 
You do not have to join this study.  If you do not join, your care at Johns Hopkins will not be affected. 
 
8. Will it cost you anything to be in this study?   
No. 
 
9. Will you be paid if you join this study? 
You will receive money for the time and inconvenience of being in the study. The amount you are paid 
will be based on the number of study visits, study doses, blood collections, cervicovaginal samples, and 
cervical biopsies.  
 
You will receive $1,400 total for your participation in the study if you keep all appointments and follow 
the instructions of the study team. $30 of the total is a bonus which may be deducted in part or whole if 
you fail to keep your appointments on time or fail to follow instruction.  All payments are made by 
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FAME 05 STUDY PROTOCOL 
B.1 Objectives 
Primary Objectives:   
 To compare the levels of tenofovir and tenofovir diphosphate in the cervicovaginal fluid, 
genital tissue, rectal fluid and blood samples using single dose gel and film formulations 
of tenofovir microbicide. 
 To compare the safety of single dose tenofovir gel and film formulations 
Secondary Objective:   
 To compare the effect of single dose tenofovir gel or film formulation on cervical tissue 
explant challenge with HIV. 
 
B.2 Study Design 
B.2.1 Identification of Study Design 
This is a single site, randomized open-label crossover study. Five subjects will receive the 
treatment sequence of gel followed by film. Five other subjects will receive the treatment 
sequence of film followed by gel. 
B.2.2 Description of Study Population 
The study population will be HIV uninfected women who meet criteria as outlined in section 5. 
B.2.3 Time to Complete Accrual 
This project will take 3 months to accrue and 6 months to complete. 
B.2.4 Study Groups 






B.2.5 Site  
The study will be carried out at the Johns Hopkins Drug Development Unit. 
 
B.3 Study Population 
B.3.1 Selection of Study Population 
The inclusion and exclusion criteria in this section will be utilized to ensure the appropriate 
selection of study participants.  
B.3.2 Recruitment 
Participants will be recruited from a variety of sources. Participants will also be referred to the 
study from other local research projects.  Recruitment materials will be approved by the Johns 
Hopkins Institutional Review Board 
B.3.3 Retention 
Once a participant is enrolled, the study site will make every effort to retain her in follow-up to 
minimize possible bias associated with loss-to-follow-up. The site will implement the following 
procedures to enhance retention: 
 Thorough explanation of the study visit schedule and procedural requirements during the 
informed consent process and re-emphasis at each study visit. 
 Thorough explanation of the importance of completing participation to the overall 
success of the study. 
 Collection of detailed locator information at the study screening visits, and active review 
and updating of this information at each subsequent visit. 
 Use of appropriate and timely visit reminder mechanisms. 





B.3.4 Inclusion Criteria 
1. 18 to 45 years of age (inclusive) with a history of receptive vaginal intercourse. 
2. HIV negative within 28 days of enrollment (Appendix 1). Note: Only non-reactive 
subjects will be enrolled. Individuals testing positive will be excluded, but confirmatory 
testing and referral for follow-up will be determined by the testing algorithm conducted 
by the Johns Hopkins Hospital Clinical Laboratory. 
3. Understand and agree to local STI reporting requirements. 
4. Able and willing to provide written informed consent to take part in the study. 
5. Able and willing to provide adequate information for locator purposes. 
6. Availability to return for all study visits, barring unforeseen circumstances. 
7. Availability to return for the second formulation dosing at the same time in the subject’s 
menstrual cycle as when the first formulation was administered, at least 10 days before 
menses. 
8. Willing to abstain from vaginal intercourse and insertion of anything (e.g., drug, vaginal 
douche, personal lubricant or sex toy) in vagina for 72 hours before each study product 
exposure, and 10 days following study product dosing, comprising a total of 26 days of 
abstinence, no insertion of vaginal products/objects while participating in the study. 
9. Willingness to have partner(s) use condoms (must not contain Nonoxynol-9) for the 
duration of the study. 
10. Agree not to participate in other research studies involving drugs and/or medical devices. 
11. Negative qualitative urine pregnancy test. 
12. Per participant report, using an effective method of contraception at enrollment; 





intrauterine device (IUD [copper or hormonal] inserted at least 30 days prior to 
enrollment) and willingness to use effective method of contraception until the completion 
of final scheduled study visit if enrolled. Female sterilization or sexual activity with 
vasectomized partner. Women abstinent from sexual activity with a male partner for the 
past 30 days and who intend to remain abstinent throughout their period of study 
participation may also be enrolled. 
13. Willingness to remain in the research unit for up to 12 hours on each of two dosing days. 
B.3.5 Exclusion Criteria 
1. Current sexual partner known by participant to be HIV seropositive. 
2. Individuals who, by history, engage in condom-less intercourse with HIV-infected 
partners, or partners that have unknown HIV serostatus, or women who exchange sex for 
money, shelter, or gifts. 
3. Active sexually transmitted infection or documented treatment of sexually transmitted 
infections including, but not limited to: chlamydia, gonorrhea, syphilis, trichomonas, 
cervicitis or PID within 8 weeks prior to enrollment. 
4. Individuals with active hepatitis B infection. 
5. Known history of genital HSV (diagnosed by either clinical or laboratory test). 
6. Symptomatic vaginal candidiasis or bacterial vaginosis. 
7. Undiagnosed irregular uterine bleeding 
8. Pathology of the female genital tract, defined as clinically apparent Grade 2 or higher 
pelvic examination finding (observed by study staff) at Screening and/or Enrollment (per 
the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse 





Female Genital Grading Table for Use in Microbicide Studies). (Note: Cervical bleeding 
associated with speculum insertion and/or specimen collection judged to be within the 
range of normal according to the clinical judgment of the IoR/designee is considered 
expected non-menstrual bleeding and is not exclusionary; Otherwise eligible participants 
with exclusionary pelvic and/or rectal examination findings may be enrolled/randomized 
after the findings have improved to a non-exclusionary severity grading or resolved.  If 
improvement to a non-exclusionary grade or resolution is documented within 42 days of 
providing informed consent, the participant may be enrolled.) 
9. Individuals who are status post hysterectomy. 
10. History of any cervicovaginal procedure (i.e. colposcopy with cervical biopsy) within the 
past 2 months.   
11. History of cone biopsy or extensive loop electrosurgical excision procedure (LEEP), 
which in the judgment of the investigator may affect permeability assessment. 
12. Any known primary or secondary uro-genital malformations, which in the assessment of 
the investigator may interfere with the intended urine collection for PK studies. 
13. Use of vaginally administered medications within 4 week of enrollment 
14. Any active urinary tract infection 
15. By history, subjects with irregular menstrual cycles. 
16. At screening: 
a. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 
1.5 X the site laboratory ULN (upper limit of normal) 
b. Hemoglobin less than 10.0 g/dL 





d. Other safety tests outside of the normal range that in the judgment of the 
investigator may interfere with conduct of the study. 
e. Positive findings on urinalysis that are clinically significant in the opinion of the 
investigator 
17. Estimated creatinine clearance < 60 ml/min based on established nomograms 
18. Recent history (past 6 months) of injection drug use or, a level of alcohol use that, in the 
judgement of the Investigator of Record, may interfere with the conduct of this study. 
19. Unwillingness to refrain from aspirin and NSAIDs product use for one week prior to and 
one week post study procedures. 
20. Use of warfarin or heparin. 
21. Use of systemic immunomodulatory medications within 4 weeks of enrollment. 
22. Use of product containing nonoxynol-9 within 4 weeks of enrollment. 
23. Use of any investigational products within 4 weeks of enrollment. 
24. Any other medical conditions deemed not safe for participation by the investigator. 
25. Any individual that is pregnant or is actively breast feeding. 
26. Post-menopausal defined as 12 months of amenorrhea. 
 
B.4 Study Product 
B.4.1 Regimen 
Subjects will be randomized to receive one of the two following sequences: 
 Single dose of Tenofovir 1% gel (equivalent to 40 mg of Tenofovir in 4 mL’s of gel),  
followed by single dose Tenofovir film (40 mg/film) 






A study clinician will administer the product with the aid of a speculum for consistency of 
placement in the region between the mid vagina and anterior fornix.   
B.4.3 Study Product Formulation   
Tenofovir Films: TFV film contains 40 mg of TFV per film 
Tenofovir Gel: The 1% tenofovir gel contains 1 gm/100 mL of PMPA (9-R-2-
phosphonomethoxypropyl adenine monohydrate), an acyclic nucleotide analogue with activity in 
vitro against retroviruses, including HIV-1 and HIV-2, as well as hepadnaviruses.(19)   
B.4.4 Study Product Supply and Accountability 
CONRAD is the IND holder for tenofovir and will ensure that packaged study product is 
provided to the Johns Hopkins Investigational Drug Service (IDS) pharmacy.  The University of 
Pittsburgh Magee Women’s Research Institute (MWRI) will provide the tenofovir film product 
to the IDS. All study products will be available to the study staff through the IDS Pharmacy. 
The IDS staff will maintain complete records of all study products received for this protocol and 
dispensed to participants.  These records will not be available to other members of the research 
staff.  Additional documentation will be required for study gel returns, destruction (if applicable) 
and other related issues as outlined in instructions for DAIDS clinical trials. All unused study 
products must be returned to the Pharmacy after the study is completed or terminated.   
B.4.5 Study Product Dispensing 
Study products will be dispensed only to enrolled participants upon receipt of a written 
prescription signed by an authorized prescriber.   





Enrolled study participants may use concomitant medications during study participation.  All 
concomitant medications, over-the-counter preparations, vitamins and nutritional supplements, 
recreational drugs, and herbal preparations will be recorded on the concomitant medications log 
form.  
All participants will be counseled to avoid the use of spermicide and other non-study vaginal 
products (other than tampons during menstruation and female condoms) while participating in 
the study.  Participants who report use of these products will be counseled regarding the use of 
alternative methods, but reported use of these products does not require any change in study 
product administration or follow-up procedures. Vaginal douching and vaginal application of 
personal lubricants will be prohibited for the ten days following dosing with a tenofovir 
formulation. Condoms provided by study staff will not be coated with any type of spermicide.   
 
B.5 Study Procedures 
This section describes visit-specific study procedures.    
B.5.1 Visit 1:  Screening Visit (within 28 days prior to Formulation #1 Dosing) 
All subjects will undergo screening procedures prior to enrollment in the protocol. Screening 
procedures may occur over several visits. Informed consent will be obtained at screening, prior 
to the procedures listed in Table 4 above.  This will be done by an interactive question and 
answer process where the potential subject will be asked specific questions to determine her 
understanding of the purpose, procedures, risks and benefits in participating in the trial.  If in the 
judgment of the investigator the subject cannot demonstrate sufficient understanding, then that 
subject will be excluded from participation in the protocol.    





 Complete history and general physical examination to determine eligibility for the study.   
 A record of concomitant medications will be obtained 
 Complete GYN examination including swab collection  to rule out STI’s 
o One cervical swab: to test for gonorrhea, chlamydia, and trichomoniasis. 
o Vaginal pH if indicated 
o Vaginal swabs for wet prep, if indicated 
o Pap smear if indicated 
 Phlebotomy to obtain blood for pregnancy test, complete metabolic panel and complete 
blood count, HIV testing, hepatitis B surface antigen and syphilis treponemal testing. 
 Urinalysis to rule out urinary tract infection.   
 Vital signs, weight, and height will be obtained. 
 Assessment for adverse events that occur over the screening period. 
 Subjects will be advised to abstain from vaginal intercourse, vaginal products, vaginal 
douche or vaginal insertion of sex toys at least 72 hours  prior to dosing of formulation # 
1 and formulation #2, and 10 days following each dosing (with the exception of study 
dosings and procedures) 
 Pregnancy testing will be repeated prior to administration of formulation #1. 
 
Subjects who meet the inclusion and exclusion criteria following the Screening Visit will be 
enrolled and randomized to a formulation sequence (gel-film or film-gel). As part of scheduling, 
care will be taken to attempt scheduling the visit at a time when the participant is not expecting 





Subjects with active vaginal bleeding at the dosing visit will not be randomized/enrolled at that 
time.  Subjects found to have vaginal bleeding on pelvic exam may be rescheduled if vaginal 
bleeding resolves before 30 days from Screening have elapsed. If vaginal bleeding does not 
resolve during the window period, and the subject expresses interest in enrollment for the study, 
she may be offered a rescreening attempt. 
B.5.2 Visits 2 & 8:  Formulation Dosing Visits 
The dose formulation will be vaginally administered by a study clinician.  
Study procedures and follow-up will then proceed as outlined in the Schedule of Events.: 
Dosing Visit Hour-by-Hour (same for gel and film) 
Day 0 (within 28 days of all screening evaluations)  
 Subject arrives at the research unit 
 Urine pregnancy test performed, required negative to continue with dose. 
 Vital signs will be obtained. 
 Medical history and concomitant medications will be reviewed and updated. 
 Symptom-directed exam will be performed. 
 Assessment for adverse events as noted from the history, and physical examination and as 
defined in section 9.3. 
-1 hour 
 Insert saline lock for PK’s 
 Pre-dose blood collection for drug concentration assessment.  
0 hour 
 Dose tenofovir formulation. 





o Plasma at following times: 0, 0.5, 1, 2, 4, 5, 8, 12 hours after dosing.  
o PBMC at following times: 0, 2, 4, 8 hours after dosing. The saline lock will be 
removed following the 12 hour pharmacokinetic time point. 
5 hours (+/- 1 hour) 
 Cervicovaginal samples (fluid sampling with an absorptive device from mid-vagina, 
fornices, exocervix,) and cervical biopsies (three biopsies for homogenate drug 
concentration and explant challenge) are being collected. 
 Rectal fluid collection 
 
During each study visit, participants will be queried for adverse events and counseled to avoid 
the use of spermicide and other non-study vaginal products (other than tampons during 
menstruation and female condoms) while participating in the study.  Study participants will be 
counseled to collect and return to the study staff any film product that comes out of the vagina 
after dosing.  
24 hours (Visits 3 and 9) 
 Blood collection for tenofovir plasma and PBMC.  
 Vital signs will be obtained. 
 Medical history and concomitant medications will be reviewed and updated. 
 Adverse event assessment 
 Symptom-directed physical exam, if needed. 
 Subject instructions including counseling to avoid the use of spermicide and other non-
study vaginal products (other than tampons during menstruation and female condoms) 





intercourse and all other insertive vaginal practices for 10 days following each 
administered dose (or 7 days after the last cervicovaginal sampling at 72 hours). 
48 hours (Visits 4 and 10) 
 Blood collection for Complete Metabolic Panel, Complete Blood Count, urinalysis (if 
clinically indicated) and tenofovir plasma concentrations.  
 Vital signs will be obtained. 
 Medical history and concomitant medications will be reviewed and updated. 
 Assessment for adverse events. 
 Symptom-directed physical exam, if needed. 
 Subject instructions including counseling to avoid the use of spermicide and other non-
study vaginal products (other than tampons during menstruation and female condoms) 
while participating on the study.  Subjects will be counseled to abstain from sexual 
intercourse and all other insertive vaginal practices for 10 days following each 
administered dose (or 7 days after the last cervicovaginal sampling at 72 hours). 
72 hours (Visits 5 and 11) 
 Blood collection for tenofovir plasma concentrations.  
 Vital signs will be obtained. 
 Medical history and concomitant medications will be reviewed and updated. 
 Assessment for adverse events. 
 Symptom-directed physical exam, if needed. 
 Cervicovaginal samples (vaginal fluid sampling from mid-vagina, fornices, exocervix,) 
and cervical biopsy (three biopsies for tissue drug concentrations and explant challenge) 





 Rectal fluid collection 
 Subject instructions including counseling to avoid the use of spermicide and other non-
study vaginal products (other than tampons during menstruation and female condoms) 
while participating on the study.  Subjects will be counseled to abstain from sexual 
intercourse and all other insertive vaginal practices for 10 days following each 
administered dose (or 7 days after the last cervicovaginal sampling at 72 hours). 
168 hours (Visits 6 and 12) 
 Blood collection for tenofovir plasma. 
 Vital signs will be obtained. 
 Medical history and concomitant medications will be reviewed and updated. 
 Assessment for adverse events. 
 Symptom-directed physical exam, if needed. 
 Cervicovaginal fluid (vaginal fluid sampling from mid-vagina, fornices, exocervix). 
 Rectal fluid collection. 
 Safety labs, including a complete metabolic panel and complete blood count and a 
urinalysis (if clinically indicated). 
 Subject instructions including counseling to avoid the use of spermicide and other non-
study vaginal products (other than tampons during menstruation and female condoms) 
while participating on the study.  Subjects will be counseled to abstain from sexual 
intercourse and all other insertive vaginal practices for 10 days following each 
administered dose (or 7 days after the last cervicovaginal sampling at 72 hours). 





Subjects will return to the research clinic at Day 14 (Visit 7) to assess their state of health post-
study. This evaluation will include a review of medical history and concomitant medications, a 
symptom-directed examination and vital signs will be obtained. Safety labs, including a complete 
metabolic panel, complete blood count, urinalysis, HIV testing, and a qualitative urine pregnancy 
test will be performed.   
Subjects are released to home with a scheduled Dosing Visit (Visit #8) appointment planned to 
coincide within one week of the time in the menstrual cycle associated with the first dosing visit.  
The first Follow-up Visit (visit 7) should follow the first Dosing Visit at 14 days (+ 2 days) The 
final Follow-up Visit (Visit 13) will occur 14 days (+2 days) after Dosing Visit #2(Visit 12). The 
events for the second Follow-up visit (Visit #13) are the same as for the first Follow-up visit 
(Visit 7). 
B.5.4 Clinical Evaluations and Procedures 
Physical exams will include the following assessments:   
 Vital signs: 
o Blood pressure 
o Pulse 
o Temperature 
o Weight (at Screening only) 
o Height (at Screening only) 
 Clinical assessments of: 
o Complete history and physical examination at screening.   
o Review of concomitant medications at screening and each study visit. 





o Interim history, including menstrual history 
o Symptom-directed examination including the following systems: 
 Genitourinary 
 Gastrointestinal 
 Systemic as needed 
Additional assessments may be performed at the discretion of the examining clinician in 
response to symptoms or illnesses present at the time of the exam. 
B.5.5 Laboratory Evaluation 
 Pregnancy test 
 Urinalysis, if clinically indicated 
 GC/CT/Trichomonas Nucleic Acid Amplification Test 
 Syphilis Chemiluminescence Assay 
 HIV Testing 




o Carbon Dioxide 
o Glucose 
o Urea Nitrogen (BUN) 
o Creatinine 
o Calcium 






o Total Bilirubin 
o Alkaline Phosphatase 
o AST 
o ALT 









 Tenofovir and metabolite drug levels in cervical tissue, cervicovaginal fluid, rectal fluid, 
plasma, and PBMCs. Metabolite drug levels to be measured in tissue and PBMC’s only. 
B.5.6 Specimen Collection and Processing 
Since samples from up to 6 compartments will be collected, standardized protocols previously  
established for sample collection, isolation of mucosal mononuclear cells from tissue (above), 
cell separation and counting, will be reviewed and amended as needed for this investigational 
protocol. 
The site will adhere to the standards of good clinical laboratory practice and site standard 





of specimens.  In cases where safety laboratory results are not available due to administrative or 
laboratory error, sites are permitted to re-draw specimens. 
B.5.7 Biohazard Containment 
As the transmission of HIV and other blood-borne pathogens can occur through contact with 
contaminated needles, blood, and blood products, appropriate blood and secretion precautions 
will be employed by all personnel in the drawing of blood and shipping and handling of all 
specimens for this study as recommended by the CDC and NIH.  All biological specimens to the 
Hopkins University lab will be transported using packaging mandated by CFR 42 Part 72.  
Biohazardous waste will be contained according to institutional, transportation/carrier, and all 
other applicable regulations 
 
B.6 Assessment of Safety and Clinical Management 
B.6.1 Safety Monitoring 
The study site investigators are responsible for continuous close safety monitoring of all study 
participants, and for alerting the Protocol Team if unexpected concerns arise. A sub-group of the 
Protocol Team, including the Protocol Chair or designee, the DAIDS Medical Officer, the 
CONRAD Medical Officer, and the External Safety Monitor will serve as the Protocol Safety 
Review Team (PSRT). Close cooperation among the PSRT and the study site will be necessary 
to monitor participant safety and respond to occurrences of toxicity in a timely manner. 
Appropriate safety monitoring will be contingent upon excellent communication between study 
participants and study staff, and upon cooperation among study staff, investigators, the External 
Safety Monitor, CONRAD Medical Officer, and the DAIDS Medical Officers. 





An External Safety Monitor who is familiar with the pertinent scientific literature related to the 
study product will be responsible for the first review of data and safety monitoring.  This 
physician, independent of the study sponsor, will be available to monitor data from this site.  
His/her minimum qualifications will include experience as a physician and experience in the 
conduct of clinical research. This individual will not receive salary or other support from the 
grant. The External (Independent) Safety Monitor model has been used successfully for other 
Johns Hopkins HIV Microbicide studies involving investigational products. The proposed 
individual will meet the qualifications outlined above and have training in the importance of the 
objective treatment of clinical safety data.   
The Data Management team for this site will generate data summaries for the External Safety 
Monitor, the DAIDS Medical Officers and CONRAD Medical Officer on a monthly basis. These 
data summaries will include adverse event, type, grade and association with the study products, 
accrual and retention data. The External Safety Monitor will evaluate adverse event data 
independently as well to determine whether or not the study protocol should continue as 
originally designed, should be changed, or should be terminated.   
Approximately once a month the PSRT will convene via teleconference to review adverse event 
data. If more urgent safety matters arise, these calls can occur more frequently.   
The IRB will be notified of any serious and unexpected adverse events according to the policies 
of the Johns Hopkins Medicine IRB. 
The following information will be submitted to the IRB at the time of renewal of a research 
protocol, as required by the IRB guidelines: 






 A summary of any assessment performed to evaluate external factors or other relevant 
information that may have an impact on the safety of study volunteers or the ethics of the 
research study; 
 A summary of the outcome of procedural reviews conducted to ensure subject privacy 
and research data confidentiality; 
 Any conclusions regarding changes to the anticipated benefit-to-risk ratio of study 
participation and final recommendations related to continuing, changing, or terminating 
the study, with accompanying rationales as appropriate. 
B.6.3 Adverse Events Definitions 
An AE is defined as any untoward medical occurrence in a clinical research participant 
administered an investigational product and which does not necessarily have a causal 
relationship with the investigational product.  As such, an AE can be an unfavorable or 
unintended sign (including an abnormal laboratory finding, for example), symptom or disease 
temporally associated with the use of an investigational product, whether or not considered 
related to the product. This definition is applied to all groups beginning from the time of 
randomization.  The term “investigational product” for this study refers to both the gel and the 
film, as well as the study gel applicator. 
Study participants will be provided instructions for contacting the study site to report any 
untoward medical occurrences they may experience, except for possible life-threatening events, 
for which they are instructed to seek immediate emergency care.  Where feasible and medically 
appropriate, participants will be encouraged to seek evaluation at Johns Hopkins Hospital, where 
the study clinicians are based, and to request that a study clinician be contacted upon their 





study medical providers related to untoward medical occurrences will be obtained for review.  
All participants reporting an untoward medical occurrence will be followed clinically until the 
occurrence resolves (returns to baseline) or stabilizes over a four week period. 
Study site staff will document in source documents all AEs reported by or observed in enrolled 
study participants regardless of severity and presumed relationship to study product.   
For each study participant, AE documentation and reporting will be undertaken throughout the 
scheduled duration of follow-up.  
The PI/designee will grade the severity of each AE and the relationship of the AE to study 
product:   
 AE severity will be graded per the DAIDS Table for Grading Adult and Pediatric 
Adverse Events, Version 1.0, December 2004 (Clarification dated August 2009) and the 
Female Genital Grading Table for Use in Microbicide Studies (Addendum 1 to the 
DAIDS Table for Grading Adult and Pediatric Adverse Events, Version 1.0, December 
2004 [Clarification dated August 2009]), except that asymptomatic BV will not be 
considered an AE. AEs not included in the Female Genital Grading Table will be graded 
by the DAIDS AE Grading Table Version 1.0, December 2004 (Clarification dated 
August 2009).  In cases where a genital AE is covered in both tables, the Female Genital 
Grading Table for Use in Microbicide Studies will be the grading scale utilized.   
 The relationship of all AEs reported on CRFs will be assessed based on the Manual for 
Expedited Reporting of Adverse Events to DAIDS, the Investigators Brochures, and the 
clinical judgment of the PI/designee.  The study products that must be considered when 






The DAIDS Table for Grading Adult and Pediatric Adverse Events, the Female Genital Grading 
Table for Use in Microbicide Studies, and Version 2.0 of the Manual for Expedited Reporting of 
Adverse Events to DAIDS are available on the DAIDS Regulatory Support Center (RSC) web 
site:   http://rsc.tech-res.com/. 
All AEs will be captured on an AE log form.  The form should be reviewed at each study visit 
and updated as needed.  For any serious or expedited AEs (SAEs/EAEs) that are continuing at a 
participant’s study exit visit, the PI/designee must establish a clinically appropriate follow-up 
plan for the AE and review with the DAIDS Medical Officers.  At a minimum, the AE must be 
re-assessed by study staff at least 2 weeks after the participant’s study exit visit; additional 
evaluations also may take place at the discretion of the PI/designee.  The same approach must be 
taken for any AEs deemed related to study product that are found to have increased in severity at 
the study exit visit.  For those AEs requiring re-assessment, if the AE has not resolved or 
stabilized at the time of re-assessment, study staff will continue to re-assess the participant at 
least once per month while the study is ongoing.  After the study has ended, all AEs requiring re-
assessment will be re-assessed at least once within the 30-60 days after the study end date.   
B.6.4 Expedited Adverse Event Reporting Requirements 
Expedited Adverse Event Reporting to DAIDS 
Requirements, definitions and methods for expedited reporting of Adverse Events (AEs) are 
outlined in Version 2.0 of the DAIDS EAE Manual, which is available on the RSC website at 
http://rsc.tech-res.com/safetyandpharmacovigilance/. The DAIDS Adverse Experience Reporting 
System (DAERS), an internet-based reporting system, must be used for expedited AE reporting 
to DAIDS. In the event of system outages or technical difficulties, expedited AEs may be 





EAE reporting procedures specific to this protocol are that once the site has submitted EAEs via 
DAERS (as above), the RSC Safety Office will also prepare the draft safety reports and send 
them to CONRAD and DAIDS Medical Officers for review. The study site will be contacted by 
the DAIDS Medical Officer if any further information or clarification is needed after the report is 
evaluated by CONRAD and DAIDS Medical Officers. The RSC Safety Office will then prepare 
the final report which will go to CONRAD for signature and submission to the FDA. Copies of 
this final report will be filed with CONRAD and RSC. Additionally, the RSC Safety Office will 
distribute safety reports to all DAIDS sites that use products under investigation in this study. 
For all EAEs submitted, sites must file an RSC update with the final or stable outcome unless the 
initial EAE submitted had a final or stable outcome noted already. 
EAE Reporting Level 
This study uses SAE category of expedited AE reporting as defined in the DAIDS EAE Manual.   
Study Agents for Expedited Reporting to DAIDS 
The study agents that must be considered in determining relationships of AEs requiring 
expedited reporting to DAIDS are:  tenofovir gel, tenofovir film, and the study gel applicator.   
Reporting Period 
AEs must be reported on an expedited basis during the entire study duration for an individual 
subject (from study enrollment until study completion or discontinuation of the subject from 
study participation for any reason). 
Participants Who Become Pregnant 
Urine pregnancy tests will be performed during the investigational protocol. Participants who 
become pregnant in follow-up will be referred for obstetric care. The participant will be 





complete metabolic panel and complete blood count. Pelvic exams will only be performed to 
evaluate a participant's reported symptom. No genital specimens will be collected in a pregnant 
participant. Staff will continue follow-up contact with the participant to obtain pregnancy 
outcome data. Of note, the participant will be encouraged to continue in the study so that safety 
data might be collected.   
B.6.5 Clinical Management of Adverse Events   
By definition, an adverse event can be either a new finding or symptom or a worsening of a pre-
existing condition. In order to accurately capture adverse events in follow-up, a thorough 
baseline history will be obtained at Visit 1 and Visit 2.  For example, for participants who report 
a history of headache, site staff will probe for and record details surrounding the condition such 
as frequency, location, duration, medication use, triggers, etc. Only by eliciting a full description 
will study staff be equipped to determine whether a subsequent event in follow-up is a clinically 
distinct event or not. 
Adverse events will be elicited during the safety contact telephone call and in-clinic follow-up 
visits. Referral to appropriate care will be offered to participants as needed. Vaginally applied 
medications should not be used if possible.  
B.6.5.1 Product Hold 
In the unlikely event that a participant is intolerant of the study product immediately after 
placement, the site clinician will perform a pelvic exam to remove all visible product. Product 
will be permanently discontinued for this participant. If a participant experiences a grade 1 or 2 
adverse event following product use, site investigators have the discretion to hold any subsequent 
product dosing until evaluation can take place in the clinic. The study product will continued to 





to resume product use. If a participant experiences a grade 3 or 4 event following product dosing, 
the site will temporarily hold any subsequent study product dosings, notify the PSRT, and await 
its recommendation regarding further product dosing. Participants who discontinue study product 
will be encouraged to remain in the study for follow up evaluations for safety. With the 
exception of pregnancy and HIV seroconversion, as outlined in Section 8.4 above, since these 
are single dose administrations of study product formulations, the study team will attempt to 
complete all evaluations associated with that dosing formulation according to the study protocol, 
so long as there is no increased risk for the study participant. 
B.6.6 Criteria for Early Termination of Study Participation 
Participants may voluntarily withdraw from the study for any reason at any time. Participants 
will be withdrawn from the study if they test positive for HIV antibody or RNA, or become 
pregnant during the study. Any participant who tests positive for HIV while enrolled in the study 
will be immediately removed from the study and referred to the appropriate care provider for 
additional counseling and treatment as necessary. HIV 4th generation EIA and RNA test results 
will be available prior to any subsequent study intervention.  
No additional doses of study drug will be given. Patients who become pregnant will not receive 
additional doses of study drug, and will be discontinued from the study, as described in Section 
B.6.4. Pregnancy outcomes will be collected for all study participants by contacting these women 
soon after anticipated parturition. After the participant’s final study contact, any pregnancy 
outcomes that meet criteria for SAE reporting as described above (e.g., congenital anomalies) 
occurring among participants will continue to be expeditiously reported.  
The Site PI/designee also may withdraw participants from the study to protect their safety and/or 





be withdrawn if the study sponsors, government or regulatory authorities, including the Office of 
Human Research Protections (OHRP), or site IRBs/ECs terminate the study prior to its planned 
end date.  Every reasonable effort is made to complete a final evaluation of participants who 
withdraw or are withdrawn from the study prior to completing follow-up.  Study staff members 
will record the reason(s) for all withdrawals in participants’ study records. 
 
B.7 Statistical Considerations 
B.7.1 Review of Study Design 
The primary aim of this study is to directly compare data among women receiving active 
microbicide in the form of a water-based gel, the delivery method most widely used in 
microbicide research currently, and novel thin film formulations of the microbicide. Urogenital, 
systemic and menstrual symptoms will be collected via symptom review with participants.  
Testing for sexually transmitted infections will occur at the screening visit to rule out other 
potential causes of reproductive tract inflammation and epithelial disruption.    PK measures will 
assess local and systemic absorption of tenofovir following single exposure. PD measures 
include ex vivo HIV explant challenge. Primary outcomes will be comparison of PK and PD 
readouts of film compared to gel formulation. Similar to the design of FAME 02, FAME 02B, 
and FAME 04, we do not plan a placebo condition for PD assessments and, there is no need for a 
placebo for PK assessments. FAME 04 will provide placebo v. active arm data for multiple 
dosing of the TFV film and gel to provide some comparator data for safety outcomes, but this is 
not critical in this small, single dose PK/PD focused study. 





Sample size of 10 will allow us to exclude differences as large as 1.2 standard deviation units 
relative to the mean when comparing film to gel results with 80% power and 5% 2-sided Type I 
error. In our experience with these intensive PK designs, this sample size has been more than 
adequate to the exploratory nature of these studies. Research participants without complete key 
data, for whatever reason, may be replaced. Key data includes plasma, cervical biopsies, and 
cervicovaginal fluid from 80% of planned collection times, each. Research participants will be 
recruited from among prior research participants in similar types of studies. It is expected to take 
3 months to accrue and 6 months to complete.  
B.7.3 Study Endpoints 
Primary Endpoint 
Pharmacokinetic (PK) 
 Systemic absorption of tenofovir 
o Systemic absorption of tenofovir will be determined following exposure as 
detected in plasma and PBMC samples as outlined in the study SOP’s.   
 Local absorption of tenofovir 
o Local absorption of tenofovir and metabolites will be determined following 
exposure as detected in genital tissue biopsy samples as outlined in the study 
SOP’s.   
 Persistence of tenofovir in cervicovaginal and rectal fluid 
o Persistence of tenofovir will be determined as detected levels of tenofovir in 







 Ex vivo explant challenge with HIV 
o Cervical tissue will be challenged ex vivo with HIV and supernatant aliquots will 
be sampled over 14 days to determine p24 antigen concentration. 
 Safety 
o Descriptive data describing adverse clinical and laboratory events will be 
categorized by treatment formulation. 
B.7.4 Blinding 
Complete concealment of allocation will not be feasible in this study.  Participants and study 
staff will not be blinded to drug formulation.   
B.7.5 Random Assignments 
Johns Hopkins IDS will prepare a randomization sequence (either gel, then film or film, then gel) 
for subjects and dispense product according to that schedule. 
B.7.6 Data Monitoring and Analysis 
B.7.6.1 Data Monitoring 
This clinical trial will be conducted in compliance with the protocol, GCP guidelines, and 
applicable regulatory requirements.  All research charts are maintained in a double locked room. 
The research staff, under the direction of the primary investigator, will create and maintain an 
electronic database on the computers in the Drug Development Unit research offices. The 
database will be backed up every night onto the appropriate server’s back-up system.  
Appropriate firewall and virus scanning software are installed and updated routinely by the 
information technology staff. 
Case report forms will be used as the first point of data entry for this protocol. Study data 





discrepancies are noted, the staff person will speak with the clinician in question as soon as 
possible to resolve the problem. The investigator will review the case report forms for 
completeness and accuracy at the end of the study.  
B.7.6.2 Safety Assessment 
Safety endpoints will be determined using all history, physical, and laboratory data prior to and 
following each of the product doses. The number of adverse events in each treatment will be 
summarized by severity, body system, and relationship to study product using frequencies, 
percent, and 95% confidence intervals. Individual participants will contribute once to the 
calculation of event rates. Differences in the proportion of participants experiencing adverse 
events among the treatment arms will be compared using Fisher’s exact tests. However, this 
Phase I study may not have an adequate sample size to detect significant differences between 
treatment arms. 
B.7.6.3 Analysis of PK Data 
Blood levels of TFV and TFV-DP will be evaluated after vaginal administration. PK parameters 
for plasma and PBMC TFV and TFV-DP will be estimated (e.g., Cmax, Tmax, AUC, 
elimination rate constant) using WinNonlin (Pharsight, Inc., Cary, NC). All PK parameters for 
plasma and PBMC as well as paired assessments of other matrices will be compared between 
formulations using a multi-level analysis (STATA/IC 11.2 for Windows software, StataCorp LP, 
College Station, TX) to assess formulation, sequence, and individual effects.   
B.7.6.4 Analysis of PD Data 
HIV explant challenge will be assessed using cumulative HIV p24 measured in culture media 
supernatant. These values will be compared between formulations using a multi-level analysis to 





evaluated for PK-PD data using sigmoid Emax modeling among other pharmacometric methods 
(WinNonlin, Pharsight, Inc. Cary, NC). 
 
B.8 Human Subject Considerations 
The investigators will make every effort to minimize risks of these products to human subjects.  
Volunteers will take part in a thorough informed consent process throughout their participation 
in the study.  Before beginning the study, the investigators will have obtained IRB approval and 
the protocol will have been submitted to the FDA.  The investigators will permit audits by the 
NIH or the FDA or any of their appointed agents. 
B.8.1 Special Populations 
Study staff will offer screening to eligible women of all ethnic and racial groups.  Members of 
the study staff are not seeking the screening or enrollment of women in special or vulnerable 
populations.  The following section also discusses special considerations for male partners of 
participants. 
Men  
Men are not included as subjects in the study because the study is testing a vaginal application of 
the study product.  The male sexual partners of women participating in this study will not be 
consented or monitored for because protocol-specified guidelines for abstinence and condom use 
are expected to protect male partners from exposure to the study product.  In addition, based on 
both preclinical and clinical data, no toxicity is anticipated from the study product.   
Children 
The NIH has mandated that children be included in research trials when appropriate.  This study 





“Justifications for Exclusion” criteria for children as set forth by the NIH.  Specifically, "the 
research topic to be studied is irrelevant to (young) children" and "a separate, age-specific study 
in (adolescent) children is warranted and preferable" at a later time. 
Prisoners 
Prisoners will not be included in this study (for screening or enrollment).  Any participants 
incarcerated during the course of participation in the trial will not be followed during their 
incarceration, and will be discontinued from the study.  Participants who have been released 
from incarceration will be permitted to return for any protocol specified follow-up or safety visits 
per the guidelines of the local IRB. 
Pregnant women 
Pregnancy is an exclusion criterion because there are no current recommendations for the use of 
tenofovir during pregnancy.  Prior to administration of study product, a urine pregnancy test will 
be performed on all women. During the informed consent process, women will be informed that 
tenofovir is not known to prevent pregnancy and that the effect of tenofovir on a developing 
human fetus is unknown.  All potential participants will be required to use a reliable method of 
contraception as outlined in the Inclusion Criteria. Women who become pregnant during the 
study period following randomization and exposure to study product will not be excluded from 
analysis. Subjects will be followed during and after pregnancy to determine outcomes. Subjects 
found to be pregnant during the study will not receive any further tenofovir formulation dosing.  
B.8.2. Informed Consent Process 
Written informed consent will be obtained from all potential study participants prior to the 
initiation of any study-related procedures.  The informed consent process will give individuals all 





participation, in this study.  Potential research participants will be encouraged to ask questions 
and to exchange information freely with the study team.  Only listed research staff may obtain 
informed consent from potential study participants.  The investigators will keep research 
participants fully informed of any new information that could affect their willingness to continue 
study participation.   
B.8.3 Risk/Benefit Statement 
Risks 
It is not expected that this trial will expose human subjects to unreasonable risk.   
1% Tenofovir Gel 
Administration of tenofovir gel intravaginally at 0.3% and 1% concentrations in the HPTN 050 
Phase I study resulted in minimal local irritation and little or no systemic AEs were identified.  
Although 92% of participants reported at least 1 AE, 87% of those reported AEs were mild, and 
70% of the AEs were limited to the genitourinary tract. Four severe AEs were reported, with 
only one, lower abdominal pain, thought to be product-related. The risks associated with 
tenofovir gel are believed to be less than those identified for systemic use. Some of the possible 
side effects of the study gel are dryness, itching, burning, or pain in the genital area.   
In the HPTN 050 Phase I study of tenofovir gel, serum PK analysis in a subset of participants 
demonstrated that there is no clinically significant systemic toxicity. Fourteen of 25 women with 
PK results had low, but detectable, serum drug levels.  Given that Phase I data demonstrate 
measurable plasma concentrations of tenofovir in some participants, participants with hepatitis B 
infection might be at risk for development of tenofovir resistant hepatitis B. However, 
participants with known hepatitis B infection will not be eligible for enrollment. It is not known 





infected participants or their partners. There is a theoretical risk that tenofovir absorbed 
systemically from tenofovir disoproxil fumarate or vaginal tenofovir gel could result in 
mutations of the HIV virus in participants who become infected with HIV during the study, or 
their partner, if the partner is infected with HIV. Limited resistance data from HPTN 050 show 
no new resistance mutations in plasma or cervicovaginal lavage specimens after 14 days of 
tenofovir gel use. No participant had high level tenofovir mutations (e.g., K65R).   
In a male tolerance study of 1% tenofovir gel, there were few genital findings observed after 
product use and all findings were classified as mild, small in size and required no treatment. The 
most common symptoms included mild pain (burning, irritation, discomfort) and pruritus. All 
reported urogenital symptoms were felt to be mild.   
In CAPRISA 004, there were no SAEs deemed related to the use of study product. No renal 
disorders were observed in the study. Mild, self-limiting diarrhea was more common among 
women who used tenofovir gel (16.9%) compared to women who used the placebo gel (11.0%). 
No tenofovir resistance was observed among the women who became infected with HIV in the 
tenofovir group. No increase in hepatic flares was observed in participants infected with the 
hepatitis B virus. There were no safety concerns in the 54 pregnancies observed in the trial.  
Tenofovir Film 
This is the second human study of TFV film and the first study is just recently underway, 
therefore, no human safety data is available. In studies of a 40 mg and 20 mg film in macaques, 
the films were inserted into pigtailed macaques daily for five days one week, followed by four 
days the next week. Safety of repeated, daily exposures was measured by repeated colposcopic 
assessment, vaginal pH, vaginal smear and microbiology tracking. Colposcopy revealed similar 





product induced tissue disruption to vaginal or cervical mucosal surfaces. Vaginal microbiology 
assessments revealed similar shifts in flora prevalence across both the tenofovir formulations and 
the placebo study arm. Vaginal pH fluctuated similarly across all three study arms. 
Polymorphonuclear cell counts determined from Gram stained vaginal smears increased 
somewhat with exposure to the higher dose tenofovir formulation compared to the lower dose 
tenofovir and the placebo arms. 
Collection of genital tissue by biopsy may cause discomfort and spotting.  On rare occasions, 
chemical cauterization and or suturing may be required if hemorrhaging occurs.  Phlebotomy or 
the intravenous catheter may lead to discomfort which may persist for the duration of the 
indwelling lock, feelings of dizziness or faintness, and/or bruising, swelling and/or infection. 
Disclosure of sexually transmitted infection (STI) may cause sadness or depression in volunteers.  
Disclosure of HIV-positive status has been associated with depression, suicidal ideation, and 
denial as well as social isolation.  Participation in clinical research includes the risks of loss of 
confidentiality and discomfort with personal nature of questions. Confinement to the clinical 
research unit for a 12 hour period may cause boredom or discomfort. 
B.8.4 Minimization of Risks 
To minimize the risk of a product being dosed to the wrong subject, study personnel will confirm 
the IDS dispensed drug with the study subject identity, per hospital protocol.  The clinical 
investigation sheet checklist will be signed off in real time to assure there is no redundant 
sampling outside the requirements of sampling called for by randomization. 
B.8.5 Benefits 
Research participants will derive no direct benefit from this single dose study. The risks of the 





HSV-2 and anti-HIV-1 activity of 1% tenofovir vaginal gel observed in CAPRISA 004, 51% and 
39% respectively, holds forth the prospect of a potential benefit for FAME-04 participants who 
are randomized to receive the tenofovir gel. Further research is anticipated to test whether 
CAPRISA 004 results will be confirmed.  Participants and others may benefit in the future from 
information learned from this study. Specifically, information learned in this study may lead to 
the development of safe and effective interventions to prevent HIV transmission. Participants 
also may appreciate the opportunity to contribute to the field of HIV prevention.  
Participants will receive HIV/STI risk reduction counseling, HIV and STI testing, physical exam, 
pelvic exam, and routine laboratory testing related to blood, liver, and kidney function. 
Participants may be provided or referred for STI treatment in accordance with CDC guidelines. 
For other medical conditions identified as part of the study screening and/or follow-up 
procedures, participants will be referred to other sources of care available in their community. 
Some volunteers may have the opportunity to access expedient treatment and decreased 
morbidity due to early diagnosis and treatment of abnormalities in serology, blood count, liver or 
kidney function tests. Lastly, the participant may appreciate the opportunity to contribute to the 
body of knowledge in the field of microbicide research. However, there is no guarantee that 
volunteers will receive any of these benefits. 
B.8.6 Compensation 
Volunteers will not be charged for any of the study visits, study supplies or examinations.  There 
are no costs to participants in this study, including overnight housing and transport provided by 
the study team.  Using the Johns Hopkins Drug Development unit remuneration schedule, 





This remuneration schedule is based on standardized payments related to the study visits and 
study-specific procedures.  
B.8.7 Participant Confidentiality 
Members of the study staff are all trained in patient confidentiality.  The log of study subject 
names and other protected health information is kept in a double locked area.  All computer 
information about study volunteers is kept on a computer with log-on passwords.    The data 
management and clinical staff are the only personnel with access to the protected health 
information of study volunteers.  Each member of the staff has log-on identification and 
password, logs off before leaving a computer screen unattended, and closes their office door 
when out of the office.  The computers used by the data groups are connected to the Johns 
Hopkins School of Medicine network, which is redundantly firewalled against penetration from 
the outside. Study-specific files are accessible only to staff of the Division of Clinical 
Pharmacology via a password-protected server. All research records will be kept for a minimum 
of five years following closure of this study.    
B.8.8 Communicable Disease Reporting 
Study staff members will comply with all local requirements to report communicable diseases 
including chlamydia, gonorrhea, syphilis, and HIV identified among study participants to the 
Baltimore City Health Department.  Study team members will include discussion of mandated 
reporting during the study informed consent process. 
B.8.9 Access to HIV-Related Care 
The investigators do not expect a screening population at high risk for HIV infection.  However, 
trained clinical staff will refer subjects who test positive or indeterminate via the HIV antibody 





indeterminate results will have standard post-test counseling as well as limited follow-up 
confirmatory testing provided by the study. Only study staff trained and experienced in HIV pre-
test and post-test counseling and who are investigators on this study will provide these study 
procedures.  Approved written materials consistent with the local clinical standard of care will 
support pre-test and post-test counseling.  Various local resources are available for medical care 
for HIV positive patients, including the Moore Clinic at Johns Hopkins University.   Subjects 
will also be offered Maryland Community Services Locator referral information.  In addition to 
referral information, subjects will be provided with information for local resources for support 
groups and other services.   
B.8.10 Study Discontinuation 
NIAID, the International Partnership for Microbicides, the US FDA, other government or 
regulatory authorities, or the Johns Hopkins Medicine Institutional Review Board may 
discontinue this study at any time.  Ongoing safety monitoring will track the incidence of AEs 
and EAEs.  In the event of an abnormal number of reported AEs and/or EAEs judged to be 
related to study gel or applicator, or any other condition deemed as an emergency event by the 
study staff, the External Safety Monitor will contact the Principal Investigator to initiate a 
temporary hold on further enrollment. 
 
B.9 Laboratory Specimens and Biohazard Containment 
B.9.1 Laboratory Specimens 
Laboratory specimens will be handled in a manner consistent with institutional, OSHA, and GLP 





Samples such as urine that will be divided for multiple analyses will be divided according to site 
SOP. Table 7 indicates the designated laboratory for sample testing. 
Table B1. Designated Labs for Testing   
Test Method Laboratory 
Urine  HCG, urinalysis JHH Clinical Laboratory 





Nucleic Acid Amplification 
test 
JHH Clinical Laboratory 
Plasma 














Complete Metabolic Panel 
Complete Blood Count 
HCG, serum 
hepatitis B surface antigen 






*CPAL, Clinical Pharmacology Analytical Laboratory, Division of Clinical Pharmacology, 
Johns Hopkins University 
B.9.2 Urine Samples 
A urinalysis will be used to screen for possible urinary tract infection when clinically indicated.  
Urine will be tested for qualitative HCG.  
B.9.3 Cervical Samples 
Biopsies to measure tenofovir drug concentrations and tissue explant susceptibility to HIV 
infection. 
B.9.4 Cervical Swabs 
C. trachomatis, N. gonorrhoeae, and trichomonas will be detected using an amplified DNA 
assay.   
HIV infection screening 
(Appendix II) 
Syphilis Chemiluminesence 
assay (with confirmatory 
RPR; FTAABS performed 
on RPR negative samples) 
Cervical tissue 
homogenate 













B.9.5 Cervicovaginal Fluid Samples 
Using Standardized Operating Procedures  for cervicovaginal  fluid collection previously 
established by the Johns Hopkins Clinical Pharmacology Analytical Laboratory, samples will be 
obtained to measure tenofovir concentrations. 
B.9.6 Rectal Fluid Samples 
Using Standardized Operating Procedures (SOP’s) previously established by the Johns Hopkins 
Clinical Pharmacology Analytical Laboratory, rectal fluid samples will be obtained via anoscopy 
to measure tenofovir concentrations.   
B.9.7 Plasma Samples 
Plasma samples will be sent to the Hopkins CPAL for assay of tenofovir concentration. 
B.9.8 Quality Control and Quality Assurance Procedures 
The Johns Hopkins Drug Development Unit and CPAL have a wealth of experience from taking 
part in several clinical studies of microbicides. Thus, all testing done in this research laboratory 
is performed with the same level of quality control as required in a licensed clinical laboratory.  
Because all of the proposed studies to be conducted in this project will be using an 
investigational product, the studies will be conducted under IND and additional measures will be 
undertaken to ensure that all protocols will be conducted under good laboratory practice. Tissue 
and fluid samples will be collected under previously established SOP’s developed by the Johns 
Hopkins Clinical Pharmacology Analytical Laboratory (CPAL).   
B.9.9 Specimen Storage and Possible Future Research Testing 
Participants will be consented for future use of vaginal and cervical specimens and blood 
samples.  Any leftover samples will be stored at CPAL for an indefinite period of time.  The 





Any results from research done on leftover specimens will not be placed in health records and 
will be kept confidential.  Informed consent will give participants the option to withdraw their 
consent for use of their specimens for future research.  The language and format employed in the 
screening and enrollment consents for these purposes are an IRB-approved means commonly 
employed in studies performed at this and other study sites within our institution to obtain 
permission for use of stored samples.  All primary study endpoints, protocol-specified testing, 
and QA/QC testing will be ascertained prior to any additional testing of stored specimens.  When 
all laboratory assays have been completed and the study has been closed, the PI for the study will 
notify the clinical site Laboratory Manager to discard all samples from volunteers in the study 
who chose to have their samples destroyed at the end of the study.  These samples will be 
discarded in the appropriate manner and the disposition will be documented. 
Biohazard Containment 
Biohazardous waste will be contained according to institutional and all other applicable 
regulations. 
 
B.10 Administrative Procedures 
The study proposal for funding, this protocol, the informed consent document, data collection 
forms, and advertising flyers are all reviewed by the Johns Hopkins School of Medicine 
Institutional Review Board prior to enrollment of participants in the study. 
B.10.1 Study Coordination 
Study implementation will follow this protocol, which may not be amended without prior written 
approval from the Sponsor and DAIDS Medical Officer.  Close coordination between protocol 





implementation, and address other issues in a timely manner.  Rates of accrual, retention, follow-
up, and AE incidence will be monitored closely by the team. 
B.10.2 Study Monitoring 
Site monitoring visits will be conducted to assess overall study compliance, as required per 
Requirements for On-Site Monitoring of DAIDS Funded and/or Sponsored Clinical Trials, GCP, 
and FDA regulations 21 CFR Part 312: 
http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/onsitemon
itor_reqs.pdf  
Study monitors will visit the site to complete the following: 
 Assess compliance with the study protocol, Good Clinical Practices (GCP) guidelines, 
and applicable regulatory requirements, including US CFR Title 45 Part 46 and Title 21 
Parts 50, 56, and 312 
 Review informed consent forms, procedures, and documentation 
 Perform source document verification to ensure the accuracy and completeness of study 
data 
 Verify proper collection and storage of biological specimens 
 Verify proper storage, dispensing, and accountability for investigational study products 
 Assess implementation and documentation of internal site quality management 
procedures 
 Assess site staff training needs 
Site investigators will allow study monitors to inspect study facilities and documentation (e.g., 
informed consent forms, clinic and laboratory records, other source documents, case report 





inspection of all study-related documentation by authorized representatives of the DAIDS, 
Sponsor and US regulatory authorities.  A site visit log will be maintained at the study sites to 
document all visits. The outcomes of the monitoring visits and the subsequent reports of 
resolutions of any identified problems will be provided to the Sponsor of the IND application. 
B.10.3 Protocol Compliance 
Amendments to the protocol will require prior written approval from the principal investigators.   
All protocol amendments will be submitted for DAIDS review and approval facilitated by the 
DAIDS Regulatory Support Center (RSC). Once approval has been provided by the RSC, such 
amendments will be submitted to the Johns Hopkins Medicine Institutional Review Board (IRB) 
for final review and approval.  Once the Johns Hopkins Medicine IRB has given final approval, 
the amendment can be implemented. 
B.10.4 Investigator’s Records 
The investigator will maintain, and store securely, complete, accurate and current study records 
throughout the study.  Study records will not be destroyed prior to receiving approval for record 
destruction from DAIDS.  Applicable records include source documents, site registration 
documents and reports, correspondence, informed consent forms, and notations of all contacts 
with the participant.   
B.10.5 Use of Information and Publications 
Publication of study results will be governed by NIH policies.  The investigators will submit any 
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1997-2001 B.A. Biology and English Literature, University of Virginia, Charlottesville, VA 
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Research Extramural Funding – Current 
6/29/06-11/30/20 A5338: An open-label, non-randomized study of pharmacokinetic interactions 
among depot medroxyprogesterone acetate (DMPA), rifampicin (RIF), and 
efavirenz (EFV) in women co-infected with human immunodeficiency virus 
(HIV) and tuberculosis (TB) 
UM1AI068636 
NIH/NIAID 
PI: Rosie Mngqibisa 
Role: Protocol Vice Chair 
1/1/14-11/30/20 Laboratory Center (LC): Microbicide Trials Network 
1-UM1AI106707-01, I/O 90057531 
NIH/NIAID 
Total direct cost per year: $222,282 
PI: Craig Hendrix 
Role: Co-I, 7%; I am involved in protocol development for several studies 
investigating novel products to prevent HIV transmission. 
 
Research Extramural Funding – Pending – n/a 
 
Research Extramural Funding – Previous 
2011-2013 Assessing the contraceptive needs of HIV-positive adolescent females compared 
to an HIV-negative cohort 
IRB Number NA_00050109 
Society of Family Planning 
Total direct costs: $66,420 
Role: PI, 50% effort 
2013-2017 Pharmacokinetics and pharmacodynamics of the etonogestrel implant when co-
administered with efavirenz 
   IRB Number NA_00087585 
American College of Obstetricians and Gynecologists/Bayer HealthCare 
Pharmaceuticals Research Fellowship in Long Acting Reversible Contraception 
Total direct cost: $19,510 
Role: PI 
6/15/10-5/31/15 FAME (Film Antiretroviral Microbicide Evaluation) 
U19AI0882639-03, JHU Subaward 4485 
NIH/NIAID 
Total direct costs: $2,809,788 
PI: Craig Hendrix 
Role: Co-I 
10/1/15-9/30/17 Post Fellowship Salary Support 
I/O 90065363 
Susan Thompson Buffett Foundation 
Total direct cost per year: $37,710 






Educational Extramural Funding – Previous 
7/12-6/14 5T32GM066691-12 and 2T32GM066691-11 
Postdoctoral Fellowship in Clinical Pharmacology, Johns Hopkins University 
SOM 
NIGMS 
Total direct costs: $251,742 and $235,590 
PI: Theresa Shapiro, MD, PhD 
Role: Fellow, 100% effort 
 
Clinical Extramural Funding – n/a 
System Innovation or Quality Improvement Extramural Funding – n/a 
Other Extramural Funding – n/a  
 
Intramural Funding 
Research Intramural Funding – n/a 
Educational Intramural Funding – Current 
2015-present Genes to Society: Reproductive Health 
 JHU SOM 
 Role: Course Coordinator, 12% effort 
 
Educational Intramural Funding – Previous – n/a 
Clinical Intramural Funding – n/a 
System Innovation or Quality Improvement Intramural Funding – n/a 
 
CLINICAL ACTIVITIES 
Clinical Focus – I am one of three attending physicians providing abortion and complex 
contraception care at JHBMC and JHH in the Division of Family Planning.  We 
are a regional referral center for women seeking medical and surgical abortions, 
as well as reversible and permanent contraception.  I also provide generalist 
OB/Gyn care in both inpatient and outpatient settings. 
 
Certification 
Medical, other state/government licensure 
2010-present Maryland medical license #D0070561, expiration 9/30/19 
2010-present DEA license #FR1880586, expiration 4/30/19 
2010-present CDS license #M70770, expiration 4/30/19 
 
Boards, other specialty certification 
2010 American Board of Obstetrics and Gynecology Written Exam 
2014 American Board of Obstetrics and Gynecology Oral Exam 
 
Clinical (Service) Responsibilities 
2010-present Johns Hopkins Bayview Medical Center – inpatient attending (Labor and 






2011-present Johns Hopkins OB/Gyn at White Marsh – outpatient attending (4-6 days per 
month) 
2012-present Women’s Center for Family Planning, Johns Hopkins Bayview Medical Center – 
outpatient attending (3-5 days per month) 
2014-present Johns Hopkins OB/Gyn at Bayview Medical Center – outpatient attending (~1 
days per month) 
 
Clinical Productivity (for FY18) 
- In-Patient OR Volume: 2 in-state, 1 out-of-state 
- Out-Patient OR Volume: 61 in-state, 2 out-of-state 
- Out-Patient Office Visits 
o Bayview: 45 in-state, 1 out-of-state 
o Women’s Center for Family Planning: 115 in-state, 1 out-of-state 
o White Marsh: 166 in-state, 4 out-of-state 
- Deliveries: 49 
- RVUs: 2450 
 
Clinical Draw – n/a 
Membership in or examiner for specialty board – n/a 
 
Clinical Program Building / Leadership 
2015-present Ryan Program Director, Johns Hopkins Bayview Medical Center – supervise 
resident training in contraception and abortion, with focus on postpartum and 
post-abortion contraception 
 
Clinical Demonstration Activities 
2011-present Presented didactics and hands-on training in manual vacuum aspiration and IUD 
insertion to medical and nursing students 1-2 times per year, JHU SOM 
2012 Led a manual vacuum aspiration training, Edward Via College of Osteopathic 
Medicine, Blacksburg VA 
 
Development of nationally/internationally recognized clinical standard of care – n/a 
 
EDUCATIONAL ACTIVITIES 
Educational Focus – I have been involved in direct teaching and training of medical students 
and residents in various aspects of contraception and abortion care, as well as 
general OB/Gyn. Since taking over as course director for the Reproductive 
Sciences block of the Genes to Society undergraduate medical school curriculum, 
I am now responsible for the medical students’ foundational knowledge of the 
reproductive system.  I am involved in teaching during the OB/Gyn clerkship, 
both in a classroom setting and in conjunction with direct patient care.  I have also 
done lectures and demonstrations on topics related to women’s health and family 









2011-present Lecturer, medical student lectures on contraception and abortion (given once 
during every 8-week rotation), JHU SOM, Baltimore MD 
2/3/12  Guest Lecturer, Clinical Aspects of Reproductive Health – “Abortion”, JHSPH, 
Baltimore MD 
3/3/14, 4/3/15 Guest Lecturer, Adolescent Sexual and Reproductive Health – “Writing for 
Advocacy”, JHSPH, Baltimore MD 
11/4/14 Small Group Preceptor, SFM Pharmacology, JHU SOM, Baltimore MD 
12/2/14 Journal Club Preceptor, SFM Pharmacology, JHU SOM, Baltimore MD 
2016-2018 Guest Lecturer, Family Planning Policies and Programs (SPH 380.655.01) – 
“Contraception: Today and Tomorrow”, JHSPH, Baltimore MD 
1/16-present Course Director, Genes to Society – Reproductive Sciences, JHU SOM, 
Baltimore MD 
   Lectured 2nd year medical students on a variety of female reproductive health 
topics, led small group and team-based learning sessions, and coordinated the 
overall course 
7/11/17  Guest Lecturer, Advanced Practice in Women’s Health (NR 110.569) – “Benign 
Pelvic Masses”, JHU SON, Baltimore MD 
5/10/18, 5/14/18 Guest Lecturer, Organ Physiology (ME 360.720), Department of Physiology – 
“Female Reproductive Physiology” and “Contraception and Assisted 
Reproductive Technology”, JHU SOM, Baltimore MD 
 





7/10-6/12 Fellow; residents and 3rd and 4th year medical students. Inpatient and outpatient 
OB/Gyn and Family Planning services. Johns Hopkins Bayview Medical Center 
7/12-present Attending; fellows, residents, and 3rd and 4th year medical students. Inpatient and 
outpatient OB/Gyn and Family Planning. Johns Hopkins Bayview Medical Center 
2/14-present Transition to the Wards: led sessions on proper surgical scrub technique for 
medical students entering clinical clerkships; JHU SOM 
6/14-present Selective Director for Medical Student Selective in Family Planning; JHU SOM 
 
National  - n/a 




10/20/14 Guest Lecturer, “We’ve Got You Covered: Immediate Postpartum Long-Acting 
Reversible Contraception”, Medstar St. Mary’s Hospital, Leonardtown MD 
4/13/15  Presenter, “Updates in Contraception for Women Living with HIV”, 25th Annual 
Clinical Care of the Patient with HIV Infection and Care of the Patients with Viral 






01/18  Association of Professors in Gynecology and Obstetrics Faculty Development 
Seminar, Manalapan FL 
   “Knowing What I Live By: Learn to Lead a Values Clarification” 
   Led a workshop instructing OB/Gyn educators on how to facilitate a values 
clarification with a variety of learners (medical students, residents, office staff, 
nurses, etc.) 
 
Workshops/seminars – n/a 
 
Mentoring 
Pre-doctoral Advisees / Mentees 
2015-present Maya Seigel, Johns Hopkins School of Medicine Class of 2019 
 
Post-doctoral Advisees / Mentees 
7/15-present Stacy Sun, MD, Gynecology and Obstetrics Class of 2018, JHU SOM 
7/15-present Sunitha Suresh, MD, Gynecology and Obstetrics Class of 2019, JHU SOM 
7/18-present Kristen Lee, MD, Gynecology and Obstetrics Class of 2022 
 
Advisees – n/a  
Thesis committees – n/a 
 
Educational Program Building/Leadership 
07/14-present Selective Director, Selective in Family Planning, OB/Gyn Clerkship, JHU SOM 
Organize and coordinate a 2-week selective for 3rd year medical students as part 
of their OB/Gyn clerkship. In addition to organizing the students’ activities while 
on the selective, I also provide direct clinical instruction. 
11/15-present Course Director (12% effort), Reproductive Sciences, Genes to Society, JHU 
SOM 
As course director, I am responsible for the overall management of this 4-week 
course that addresses male and female reproductive systems.  This involves 
developing the overall curriculum related to reproductive health, managing the 
course schedule, and coordinating presenters.  During the course itself, I am 
responsible for delivering several lectures on a variety of topics, leading small 
group discussions and interactive sessions, and proctoring quizzes and exams. 
06/18-present Site Director, Visiting Resident Rotation for OB/Gyn Residents from Walter Reed 
National Military Medical Center 
09/18-present Member, Education Policy and Curriculum Committee, Johns Hopkins School of 
Medicine 
   Represent Genes to Society, Year 2 curriculum 
  










- Drug interactions 
- Clinical pharmacology 
- Microbicides 
 
Research Program Building / Leadership – n/a 
Research Demonstration Activities – n/a 
Inventions, Patents, Copyrights – n/a 
Technology Transfer Activities – n/a 
 
SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES 
System Innovation Focus – n/a 
 
System Innovation and Quality Improvement efforts within JHMI: 
2016-2017 Beta Team member, Gyn/OB Departmental effort to improve processes for 




Institutional Administrative Appointments – n/a 
 
Editorial Activities 
Editorial Board Appointments – n/a 
 
Journal peer review activities 
2014-present Obstetrics and Gynecology 
5/15-present PLoS ONE 
 
Other peer review activities – n/a 
 
Advisory Committees, Review Groups/Study Sections 
10/14-present Member, AIDS Clinical Trials Group Clinical Pharmacology Advisory Group 
  
Professional Societies 
2006-present American College of Obstetricians and Gynecologists 
   2006-2014 Junior Fellow 
   2014-present Fellow 
2009-present Member, Association of Reproductive Health Professionals 
2010-present Junior Fellow, Society of Family Planning 
2011-present Member, National Abortion Federation 
2011-present Member, Physicians for Reproductive Health 
2017-present Member, Association of Professors of Gynecology and Obstetrics 
 
Conference Organizer – n/a 







7/2015-4/2017 Member, World Health Organization Technical Consultation on drug interactions 




2016  Nominated for W. Barry Wood Jr. Award for Excellence in Teaching 
   This award is given annually to two faculty members from the pre-clinical 
medical school curriculum who are recognized as being the most inspirational 
and/or effective teachers by students. 
2017  Semi-Finalist for the Distinguished Teaching Society of JHUSOM 
2018  Nominated for George J Stuart Award for Outstanding Clinical Teaching 
   This award is given annually by the senior medical school class to an outstanding 
clinical teacher in the school of medicine. 
2018  Semi-Finalist for the Distinguished Teaching Society of JHUSOM 
2018  Excellence in Teaching and Mentorship Award from the Gyn/OB Residency 
Class of 2018, JHUSOM 
2018  APGO Excellence in Teaching Award, Department of Gynecology and 
Obstetrics, JHUSOM 
2019  Excellence in Teaching and Mentorship Award from the Gyn/OB Residency 




6/14/11 Grand Rounds Speaker, Drexel University College of Medicine/Hahnemann 
University Hospital Department of Obstetrics and Gynecology, “Emergency 
Contraception Update”, Philadelphia PA 
12/10/11 Speaker and trainer, Student National Medical Association Regional Conference, 
“Long-acting Reversible Contraceptives”, Baltimore MD 
2/1/14 Speaker, Law Students for Reproductive Justice Mid-Atlantic/Northeast Regional 
Conference, “Being an Abortion Provider”, Washington DC 
7/29/14 Speaker, Urban Health Residency Noon Conference, Johns Hopkins University 
SOM, “Politics and Reproductive Health in the United States: A Sobering 
Update”, Baltimore MD 
9/3/14 Speaker, Internal Medicine Resident Education, Johns Hopkins Bayview Medical 
Center, “Contraceptive Methods” 
4/13/15 Presentation at regional HIV conference 
4/3/18 Grand Rounds Speaker, Drexel University College of Medicine/Hahnemann 
University Hospital Department of Obstetrics and Gynecology, “Multipurpose 
Prevention Technologies: New solutions for old problems”, Philadelphia PA 
10/11/18 Grand Rounds Speaker, Johns Hopkins University School of Medicine, 
Department of Gynecology and Obstetrics, “Family Planning Updates”, Baltimore 
MD 
10/25/18 Grand Rounds Speaker, Sinai Hospital, Department of Obstetrics and 







11/5/11 Medical Students for Choice National Conference, Baltimore MD 
Panelist, “Being an Abortion Provider 
Trainer, “Manual Vacuum Aspiration Workshop” 
10/25/14 Presenter, Doctors for America National Leadership Conference, “Advocacy 
Skills for Abortion Providers”, Baltimore MD 
 
International 
11/30/11 International Conference on Family Planning, Dakar, Senegal 
Trainer, Contraceptive Implant Insertion and Removal, Clinical Training in Long-
Acting and Permanent Methods and Injectables 
Panelist, post-abortion provision of long-acting reversible contraceptive methods 
11/14/13 International Conference on Family Planning, Addis Ababa, Ethiopia 
Presenter, Contraception for Special Populations 
Trainer, Contraceptive Implant Insertion and Removal 
 
OTHER PROFESSIONAL ACCOMPLISHMENTS 
Posters 
4/28/14  Robinson JA, Fox MC, Jamshidi R, Trent M, Anderson J, Burke AE. 
Contraceptive needs of HIV-infected adolescent women: a qualitative analysis. 
American College of Obstetricians and Gynecologists Annual Clinical Meeting, 
Chicago IL 
4/28/14  Robinson, JA, Fox MC, Jamshidi R, Trent M, Anderson J, Burke AE. 
Contraceptive needs of HIV-positive adolescent women compared to an HIV-
negative cohort. American College of Obstetricians and Gynecologists Annual 
Clinical Meeting, Chicago IL 
 
Community Services 
Oct. 2014-March 2015 Volunteered on Reproductive Health Van, Baltimore City Health 
Department, Baltimore MD 
 
Humanitarian Activities 
May-June 2012 Volunteer with American Refugee Committee, Tak Province, Thailand 
 
2011-2012 Leadership Training Academy, Physicians for Reproductive Health, Washington 
DC and New York NY 
 
